PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 30677052-0 2019 The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma. obeticholic acid 16-32 nuclear receptor subfamily 1 group H member 4 Homo sapiens 4-7 30677052-4 2019 Our aim was to evaluate, in primary cultures of human intrahepatic CCA (iCCA), the effects of the FXR agonist obeticholic acid (OCA), a semisynthetic bile acid derivative, on their cancerogenic potential. obeticholic acid 110-126 nuclear receptor subfamily 1 group H member 4 Homo sapiens 98-101 30677052-4 2019 Our aim was to evaluate, in primary cultures of human intrahepatic CCA (iCCA), the effects of the FXR agonist obeticholic acid (OCA), a semisynthetic bile acid derivative, on their cancerogenic potential. obeticholic acid 128-131 nuclear receptor subfamily 1 group H member 4 Homo sapiens 98-101 31201556-10 2019 Therefore, targeting FXR has been exploited in different animal models of both intrahepatic and obstructive cholestasis, and the first FXR agonist obeticholic acid (OCA) has been approved for the treatment of primary biliary cholangitis (PBC). obeticholic acid 147-163 nuclear receptor subfamily 1 group H member 4 Homo sapiens 135-138 31201556-10 2019 Therefore, targeting FXR has been exploited in different animal models of both intrahepatic and obstructive cholestasis, and the first FXR agonist obeticholic acid (OCA) has been approved for the treatment of primary biliary cholangitis (PBC). obeticholic acid 165-168 nuclear receptor subfamily 1 group H member 4 Homo sapiens 135-138 30468885-4 2019 We investigated the effects of obeticholic acid (OCA), an agonist of FXR, on Lipopolysaccharide (LPS)-induced ALI in mice. obeticholic acid 31-47 nuclear receptor subfamily 1, group H, member 4 Mus musculus 69-72 30682184-4 2019 Obeticholic acid, an FXR agonist, stimulates FGF19 and has shown therapeutic potential in both BA diarrhea and in NAFLD. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 21-24 30682184-4 2019 Obeticholic acid, an FXR agonist, stimulates FGF19 and has shown therapeutic potential in both BA diarrhea and in NAFLD. obeticholic acid 0-16 fibroblast growth factor 19 Homo sapiens 45-50 30144429-0 2018 FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid. obeticholic acid 94-110 nuclear receptor subfamily 1 group H member 4 Homo sapiens 0-3 31197565-3 2019 Clinical efficacy superior to most other treatment options was shown by FXR agonists such as obeticholic acid (OCA) as they improved various metabolic features including liver steatosis as well as liver inflammation and fibrosis. obeticholic acid 111-114 nuclear receptor subfamily 1 group H member 4 Homo sapiens 72-75 31201552-2 2019 OCA, also known as 6-ethyl-CDCA or INT-747, was originally described by investigators at the Perugia University in 2002 as a selective ligand for the bile acid sensor, farnesoid-X-receptor (FXR). obeticholic acid 19-31 nuclear receptor subfamily 1 group H member 4 Homo sapiens 168-188 31201552-2 2019 OCA, also known as 6-ethyl-CDCA or INT-747, was originally described by investigators at the Perugia University in 2002 as a selective ligand for the bile acid sensor, farnesoid-X-receptor (FXR). obeticholic acid 19-31 nuclear receptor subfamily 1 group H member 4 Homo sapiens 190-193 30409980-0 2018 FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis. obeticholic acid 12-28 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 0-3 30259754-5 2018 EXPERT OPINION: Despite the development of numerous FXR modulators, which culminated in the successful launch of obeticholic acid (OCA), it remains a matter of debate on how the function of FXR should be exploited for therapeutic purposes. obeticholic acid 113-129 nuclear receptor subfamily 1 group H member 4 Homo sapiens 52-55 30196109-2 2018 The present study investigated the effects of obeticholic acid (OCA), a novel synthetic FXR agonist, on renal inflammation and oxidative stress in a model of sepsis-induced acute kidney injury. obeticholic acid 46-62 bone gamma carboxyglutamate protein Mus musculus 64-67 30354208-0 2018 Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice. obeticholic acid 35-51 low density lipoprotein receptor Mus musculus 67-99 30354208-1 2018 Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions. obeticholic acid 116-132 nuclear receptor subfamily 1, group H, member 4 Mus musculus 108-111 30354208-1 2018 Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions. obeticholic acid 116-132 nuclear receptor subfamily 1, group H, member 4 Mus musculus 151-154 30354208-1 2018 Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions. obeticholic acid 116-132 low density lipoprotein receptor Mus musculus 180-212 30354208-1 2018 Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions. obeticholic acid 116-132 low density lipoprotein receptor Mus musculus 214-218 30354208-1 2018 Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions. obeticholic acid 134-137 nuclear receptor subfamily 1, group H, member 4 Mus musculus 108-111 30354208-1 2018 Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions. obeticholic acid 134-137 nuclear receptor subfamily 1, group H, member 4 Mus musculus 151-154 30354208-1 2018 Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions. obeticholic acid 134-137 low density lipoprotein receptor Mus musculus 180-212 30354208-1 2018 Objective- The objective of this study was to determine whether and how activation of farnesoid X receptor (FXR) by obeticholic acid (OCA), a clinical FXR agonist, modulates liver low-density lipoprotein receptor (LDLR) expression under normolipidemic conditions. obeticholic acid 134-137 low density lipoprotein receptor Mus musculus 214-218 30556039-0 2018 Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-.Leiden Mice. obeticholic acid 0-16 low density lipoprotein receptor Homo sapiens 150-154 30411084-2 2018 The FXR agonist obeticholic acid (OCA) is licensed for the treatment of primary biliary cholangitis and has shown promising results in NASH patients, whereas TGR5 agonists target inflammation and metabolism. obeticholic acid 16-32 nuclear receptor subfamily 1 group H member 4 Homo sapiens 4-7 30314377-6 2018 Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 53-56 30314377-6 2018 Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 53-56 30261763-5 2018 This explains the manifold metabolic pathways as antifibrotic targets, including farnesoid X receptor (FXR) agonism (obeticholic acid, nonsteroidal FXR agonists), acetyl-CoA carboxylase inhibition, peroxisome proliferator-activator receptor agonism (elafibranor, lanifibranor, saroglitazar), and fibroblast growth factor (FGF)-21 or FGF-19 activation. obeticholic acid 117-133 nuclear receptor subfamily 1 group H member 4 Homo sapiens 103-106 30254132-7 2018 Obeticholic acid dose dependently inhibited lipid accumulation and modulated gene expression downstream of the farnesoid X receptor. obeticholic acid 0-16 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 121-131 29871716-8 2018 Consistent with this model, cholic acid feeding, obeticholic acid administration, and liver HNF4alpha knockdown reduced hepatic CSAD expression, while liver SHP knockout and apical sodium-dependent bile acid transporter (ASBT) inhibitor treatment induced hepatic CSAD expression in mice. obeticholic acid 49-65 cysteine sulfinic acid decarboxylase Mus musculus 128-132 30026040-1 2018 Activation of the nuclear farnesoid X receptor (FXR) which acts as cellular bile acid sensor has been validated as therapeutic strategy to counter liver disorders such as non-alcoholic steatohepatitis by the clinical efficacy of obeticholic acid. obeticholic acid 229-245 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 36-46 30026040-1 2018 Activation of the nuclear farnesoid X receptor (FXR) which acts as cellular bile acid sensor has been validated as therapeutic strategy to counter liver disorders such as non-alcoholic steatohepatitis by the clinical efficacy of obeticholic acid. obeticholic acid 229-245 nuclear receptor subfamily 1 group H member 4 Homo sapiens 48-51 29733835-5 2018 We also investigated whether obeticholic acid (OCA), an farnesoid X receptor agonist, affects MAFG expression and how it contributes to tumor growth in mice. obeticholic acid 29-45 v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian) Mus musculus 94-98 29028769-11 2018 INT-747 enhanced Caco-2 cell viability and inhibited inflammatory response by blocking the NF-kappaB pathway after OGD/R injury, which was diminished by a CSE-specific inhibitor (PAG). obeticholic acid 0-7 nuclear factor kappa B subunit 1 Homo sapiens 91-100 29028769-11 2018 INT-747 enhanced Caco-2 cell viability and inhibited inflammatory response by blocking the NF-kappaB pathway after OGD/R injury, which was diminished by a CSE-specific inhibitor (PAG). obeticholic acid 0-7 cystathionase (cystathionine gamma-lyase) Mus musculus 155-158 29530598-3 2018 While targeting FXR holds promise, 6-ethyl-CDCA known as obeticholic acid, the first in class of FXR ligands, causes side effects, partially because the lack of selectivity toward GPBAR1, a putative itching receptor. obeticholic acid 35-47 nuclear receptor subfamily 1, group H, member 4 Mus musculus 97-100 29743187-3 2018 Mice were fed an HFD to induce NAFLD and then treated with the FXR ligand obeticholic acid (OCA). obeticholic acid 74-90 nuclear receptor subfamily 1, group H, member 4 Mus musculus 63-66 29743187-3 2018 Mice were fed an HFD to induce NAFLD and then treated with the FXR ligand obeticholic acid (OCA). obeticholic acid 92-95 nuclear receptor subfamily 1, group H, member 4 Mus musculus 63-66 30393515-0 2018 Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking. obeticholic acid 39-46 nuclear receptor subfamily 1 group H member 4 Homo sapiens 17-20 29559521-0 2018 FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. obeticholic acid 18-34 nuclear receptor subfamily 1 group H member 4 Homo sapiens 0-3 29559521-1 2018 Obeticholic acid (OCA) is a selective farnesoid X receptor (FXR) agonist that regulates bile acid and lipid metabolism. obeticholic acid 0-16 nuclear receptor subfamily 1, group H, member 4 Mus musculus 38-58 29559521-1 2018 Obeticholic acid (OCA) is a selective farnesoid X receptor (FXR) agonist that regulates bile acid and lipid metabolism. obeticholic acid 0-16 nuclear receptor subfamily 1, group H, member 4 Mus musculus 60-63 29559521-1 2018 Obeticholic acid (OCA) is a selective farnesoid X receptor (FXR) agonist that regulates bile acid and lipid metabolism. obeticholic acid 18-21 nuclear receptor subfamily 1, group H, member 4 Mus musculus 38-58 29559521-1 2018 Obeticholic acid (OCA) is a selective farnesoid X receptor (FXR) agonist that regulates bile acid and lipid metabolism. obeticholic acid 18-21 nuclear receptor subfamily 1, group H, member 4 Mus musculus 60-63 29660435-2 2018 Recently obeticholic acid (OCA) which is a farnesoid X receptor (FXR) agonist was approved by FDA to treat cholestatic liver diseases, which provided us a newly therapeutic strategy against cholestasis. obeticholic acid 9-25 nuclear receptor subfamily 1, group H, member 4 Mus musculus 65-68 29660435-2 2018 Recently obeticholic acid (OCA) which is a farnesoid X receptor (FXR) agonist was approved by FDA to treat cholestatic liver diseases, which provided us a newly therapeutic strategy against cholestasis. obeticholic acid 27-30 nuclear receptor subfamily 1, group H, member 4 Mus musculus 65-68 29802399-1 2018 Accumulating evidence has suggested that farnesoid X receptor (FXR) agonists, such as obeticholic acid (OCA) are therapeutically useful for non-alcoholic steatohepatitis (NASH). obeticholic acid 86-102 nuclear receptor subfamily 1, group H, member 4 Mus musculus 41-61 29802399-1 2018 Accumulating evidence has suggested that farnesoid X receptor (FXR) agonists, such as obeticholic acid (OCA) are therapeutically useful for non-alcoholic steatohepatitis (NASH). obeticholic acid 86-102 nuclear receptor subfamily 1, group H, member 4 Mus musculus 63-66 29802399-1 2018 Accumulating evidence has suggested that farnesoid X receptor (FXR) agonists, such as obeticholic acid (OCA) are therapeutically useful for non-alcoholic steatohepatitis (NASH). obeticholic acid 104-107 nuclear receptor subfamily 1, group H, member 4 Mus musculus 41-61 29802399-1 2018 Accumulating evidence has suggested that farnesoid X receptor (FXR) agonists, such as obeticholic acid (OCA) are therapeutically useful for non-alcoholic steatohepatitis (NASH). obeticholic acid 104-107 nuclear receptor subfamily 1, group H, member 4 Mus musculus 63-66 29802399-4 2018 Treatment with OCA effectively prevented chronic inflammation and liver fibrosis in WD-fed MC4R-KO mice with only marginal effect on body weight and hepatic steatosis. obeticholic acid 15-18 melanocortin 4 receptor Mus musculus 91-95 29802399-6 2018 Intriguingly, treatment with OCA markedly reduced hCLS formation even after MC4R-KO mice developed NASH, thereby inhibiting the progression of liver fibrosis. obeticholic acid 29-32 cardiolipin synthase 1 Homo sapiens 50-54 29802399-6 2018 Intriguingly, treatment with OCA markedly reduced hCLS formation even after MC4R-KO mice developed NASH, thereby inhibiting the progression of liver fibrosis. obeticholic acid 29-32 melanocortin 4 receptor Mus musculus 76-80 29649907-5 2018 EXPERT OPINION: While the first FXR agonist, obeticholic acid, has gained approval, significant safety issues have been emerged. obeticholic acid 45-61 nuclear receptor subfamily 1 group H member 4 Homo sapiens 32-35 29487110-0 2018 Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms. obeticholic acid 30-46 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 10-20 29487110-2 2018 FXR agonists, obeticholic acid (OCA) and chenodeoxycholic acid (CDCA), increase mRNA expression of efflux transporters in sandwich-cultured human hepatocytes (SCHH). obeticholic acid 14-30 nuclear receptor subfamily 1 group H member 4 Homo sapiens 0-3 29487110-2 2018 FXR agonists, obeticholic acid (OCA) and chenodeoxycholic acid (CDCA), increase mRNA expression of efflux transporters in sandwich-cultured human hepatocytes (SCHH). obeticholic acid 32-35 nuclear receptor subfamily 1 group H member 4 Homo sapiens 0-3 29377207-7 2018 XBP1 pathway activation increased in Huh7-Ntcp and HepG2 cells treated with bile acids, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) or GW4064. obeticholic acid 88-122 X-box binding protein 1 Homo sapiens 0-4 29377207-7 2018 XBP1 pathway activation increased in Huh7-Ntcp and HepG2 cells treated with bile acids, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) or GW4064. obeticholic acid 88-122 MIR7-3 host gene Homo sapiens 37-41 29377207-7 2018 XBP1 pathway activation increased in Huh7-Ntcp and HepG2 cells treated with bile acids, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) or GW4064. obeticholic acid 88-122 solute carrier family 10 member 1 Homo sapiens 42-46 29377207-7 2018 XBP1 pathway activation increased in Huh7-Ntcp and HepG2 cells treated with bile acids, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) or GW4064. obeticholic acid 124-131 X-box binding protein 1 Homo sapiens 0-4 29377207-7 2018 XBP1 pathway activation increased in Huh7-Ntcp and HepG2 cells treated with bile acids, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) or GW4064. obeticholic acid 124-131 MIR7-3 host gene Homo sapiens 37-41 29377207-7 2018 XBP1 pathway activation increased in Huh7-Ntcp and HepG2 cells treated with bile acids, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) or GW4064. obeticholic acid 124-131 solute carrier family 10 member 1 Homo sapiens 42-46 29958417-4 2018 FXR agonists (chenodeoxycholic acid, GW4064, and obeticholic acid):but not an antagonist (guggulsterone)&mdash;induced actin polymerization and expression of N-cadherin and phosphorylated focal adhesion kinase, although they were less effective than transforming growth factor beta (TGF-beta). obeticholic acid 49-65 nuclear receptor subfamily 1 group H member 4 Homo sapiens 0-3 29958417-4 2018 FXR agonists (chenodeoxycholic acid, GW4064, and obeticholic acid):but not an antagonist (guggulsterone)&mdash;induced actin polymerization and expression of N-cadherin and phosphorylated focal adhesion kinase, although they were less effective than transforming growth factor beta (TGF-beta). obeticholic acid 49-65 cadherin 2 Homo sapiens 162-172 29958417-4 2018 FXR agonists (chenodeoxycholic acid, GW4064, and obeticholic acid):but not an antagonist (guggulsterone)&mdash;induced actin polymerization and expression of N-cadherin and phosphorylated focal adhesion kinase, although they were less effective than transforming growth factor beta (TGF-beta). obeticholic acid 49-65 transforming growth factor beta 1 Homo sapiens 254-285 29958417-4 2018 FXR agonists (chenodeoxycholic acid, GW4064, and obeticholic acid):but not an antagonist (guggulsterone)&mdash;induced actin polymerization and expression of N-cadherin and phosphorylated focal adhesion kinase, although they were less effective than transforming growth factor beta (TGF-beta). obeticholic acid 49-65 transforming growth factor beta 1 Homo sapiens 287-295 29530598-3 2018 While targeting FXR holds promise, 6-ethyl-CDCA known as obeticholic acid, the first in class of FXR ligands, causes side effects, partially because the lack of selectivity toward GPBAR1, a putative itching receptor. obeticholic acid 57-73 nuclear receptor subfamily 1, group H, member 4 Mus musculus 97-100 29530598-3 2018 While targeting FXR holds promise, 6-ethyl-CDCA known as obeticholic acid, the first in class of FXR ligands, causes side effects, partially because the lack of selectivity toward GPBAR1, a putative itching receptor. obeticholic acid 57-73 G protein-coupled bile acid receptor 1 Mus musculus 180-186 29512910-0 2018 Editorial: weight change, liver histology and the metabolic effects of obeticholic acid in NASH. obeticholic acid 71-87 SAM domain, SH3 domain and nuclear localization signals 1 Homo sapiens 91-95 30001540-13 2018 Obeticholic acid, an agonist of FXR, inhibited IL-6 production, tumor growth and lung metastasis of ICC in vivo. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 32-35 29761165-5 2018 Recently, the U.S. Food and Drug Administration approved obeticholic acid to be used in certain patients with PBC. obeticholic acid 57-73 dihydrolipoamide S-acetyltransferase Homo sapiens 110-113 29928160-4 2018 Several models have been developed, including the UK-PBC and GLOBE scores, to assist in identifying patients who may benefit from second-line therapies, such as the farnesoid X receptor (FXR) agonist obeticholic acid (OCA). obeticholic acid 200-216 nuclear receptor subfamily 1 group H member 4 Homo sapiens 165-185 29928160-4 2018 Several models have been developed, including the UK-PBC and GLOBE scores, to assist in identifying patients who may benefit from second-line therapies, such as the farnesoid X receptor (FXR) agonist obeticholic acid (OCA). obeticholic acid 200-216 nuclear receptor subfamily 1 group H member 4 Homo sapiens 187-190 29928160-4 2018 Several models have been developed, including the UK-PBC and GLOBE scores, to assist in identifying patients who may benefit from second-line therapies, such as the farnesoid X receptor (FXR) agonist obeticholic acid (OCA). obeticholic acid 218-221 nuclear receptor subfamily 1 group H member 4 Homo sapiens 165-185 29928160-4 2018 Several models have been developed, including the UK-PBC and GLOBE scores, to assist in identifying patients who may benefit from second-line therapies, such as the farnesoid X receptor (FXR) agonist obeticholic acid (OCA). obeticholic acid 218-221 nuclear receptor subfamily 1 group H member 4 Homo sapiens 187-190 29346429-0 2018 The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury. obeticholic acid 33-49 solute carrier family 47 member 1 Rattus norvegicus 115-121 28746779-1 2018 BACKGROUND & AIMS: Treatment with the farnesoid X receptor (FXR) agonist obeticholic acid is ineffective in some patients with non-alcoholic steatohepatitis (NASH) but the explanation is uncertain. obeticholic acid 77-93 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 52-62 28746779-1 2018 BACKGROUND & AIMS: Treatment with the farnesoid X receptor (FXR) agonist obeticholic acid is ineffective in some patients with non-alcoholic steatohepatitis (NASH) but the explanation is uncertain. obeticholic acid 77-93 nuclear receptor subfamily 1 group H member 4 Homo sapiens 64-67 29110023-2 2018 This changed at the end of 2016 when obeticholic acid was licensed in Europe for PBC patients not responding to UDCA. obeticholic acid 37-53 dihydrolipoamide S-acetyltransferase Homo sapiens 81-84 30001540-13 2018 Obeticholic acid, an agonist of FXR, inhibited IL-6 production, tumor growth and lung metastasis of ICC in vivo. obeticholic acid 0-16 interleukin 6 Homo sapiens 47-51 29174575-3 2017 Whether FXR activation by its agonist obeticholic acid (OCA) is contributed to improve sepsis-induced liver injury remains unknown. obeticholic acid 38-54 nuclear receptor subfamily 1, group H, member 4 Mus musculus 8-11 28987596-1 2017 Recently obeticholic acid (OCA) which is a farnesoid X receptor (FXR) agonist was approved by FDA to treat cholestatic liver diseases, which provided us a novel therapeutic strategy against cholestasis. obeticholic acid 9-25 nuclear receptor subfamily 1, group H, member 4 Mus musculus 65-68 28987596-1 2017 Recently obeticholic acid (OCA) which is a farnesoid X receptor (FXR) agonist was approved by FDA to treat cholestatic liver diseases, which provided us a novel therapeutic strategy against cholestasis. obeticholic acid 27-30 nuclear receptor subfamily 1, group H, member 4 Mus musculus 65-68 29174575-3 2017 Whether FXR activation by its agonist obeticholic acid (OCA) is contributed to improve sepsis-induced liver injury remains unknown. obeticholic acid 56-59 nuclear receptor subfamily 1, group H, member 4 Mus musculus 8-11 28949776-4 2017 Obeticholic acid (OCA) is the most clinically advanced bile acid-derived agonist for FXR-mediated anti-inflammatory and anti-fibrotic effects. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 85-88 29226620-0 2017 Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models. obeticholic acid 23-39 nuclear receptor subfamily 1 group H member 4 Homo sapiens 66-69 29226620-1 2017 Obeticholic acid (OCA) is a semisynthetic farnesoid X receptor (FXR) agonist, an analogue of chenodeoxycholic acid (CDCA) which is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA). obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 64-67 29226620-1 2017 Obeticholic acid (OCA) is a semisynthetic farnesoid X receptor (FXR) agonist, an analogue of chenodeoxycholic acid (CDCA) which is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA). obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 64-67 28949776-4 2017 Obeticholic acid (OCA) is the most clinically advanced bile acid-derived agonist for FXR-mediated anti-inflammatory and anti-fibrotic effects. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 85-88 31966664-0 2017 Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation. obeticholic acid 0-16 NLR family, pyrin domain containing 3 Mus musculus 75-80 28852062-5 2017 In mice pretreated with 6-ethyl-chenodeoxycholic acid (6-ECDCA), a selective FXR agonist, I/R induced changes were prevented and renal function and structure were improved. obeticholic acid 24-53 nuclear receptor subfamily 1, group H, member 4 Mus musculus 77-80 28852062-5 2017 In mice pretreated with 6-ethyl-chenodeoxycholic acid (6-ECDCA), a selective FXR agonist, I/R induced changes were prevented and renal function and structure were improved. obeticholic acid 55-62 nuclear receptor subfamily 1, group H, member 4 Mus musculus 77-80 29259742-2 2017 Obeticholic acid (INT-747), a FXR agonist, has advanced into clinical phase III trials in patients with nonalcoholic steatohepatitis (NASH), but adverse effects (e.g., pruritus, LDL increase) were observed. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 30-33 28970500-0 2017 The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway. obeticholic acid 17-33 nuclear receptor subfamily 1 group H member 4 Homo sapiens 4-7 28970500-0 2017 The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway. obeticholic acid 17-33 interleukin 6 Homo sapiens 90-94 28970500-0 2017 The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway. obeticholic acid 17-33 signal transducer and activator of transcription 3 Homo sapiens 95-100 28970500-3 2017 This study aimed at investigating the potential effect of the FXR agonist, obeticholic acid (OCA), on HCC and the involvement of IL-6/STAT3 pathway. obeticholic acid 75-91 nuclear receptor subfamily 1 group H member 4 Homo sapiens 62-65 28970500-3 2017 This study aimed at investigating the potential effect of the FXR agonist, obeticholic acid (OCA), on HCC and the involvement of IL-6/STAT3 pathway. obeticholic acid 93-96 nuclear receptor subfamily 1 group H member 4 Homo sapiens 62-65 28852062-8 2017 In further experiments administering 6-ECDCA to renal proximal tubular cells cultured under hypoxia, the renoprotective effects of FXR activation were associated with inhibition of oxidative and ER stress and with increased antioxidant activity. obeticholic acid 37-44 nuclear receptor subfamily 1, group H, member 4 Mus musculus 131-134 28805978-0 2017 Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes. obeticholic acid 0-16 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 40-50 28805978-3 2017 Obeticholic acid (OCA) is a potent and selective FXR agonist that is 100-fold more potent than the endogenous ligand chenodeoxycholic acid (CDCA). obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 49-52 28805978-3 2017 Obeticholic acid (OCA) is a potent and selective FXR agonist that is 100-fold more potent than the endogenous ligand chenodeoxycholic acid (CDCA). obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 49-52 28406477-5 2017 Strikingly, miR-21 knockout mice fed the FF diet supplemented with farnesoid X receptor (FXR) agonist obeticholic acid (OCA) display minimal steatosis, inflammation, oxidative stress and cholesterol accumulation. obeticholic acid 102-118 microRNA 21a Mus musculus 12-18 29098111-9 2017 The FXR agonist obeticholic acid has had beneficial effects on NASH in recent clinical trials. obeticholic acid 16-32 nuclear receptor subfamily 1 group H member 4 Homo sapiens 4-7 28406477-5 2017 Strikingly, miR-21 knockout mice fed the FF diet supplemented with farnesoid X receptor (FXR) agonist obeticholic acid (OCA) display minimal steatosis, inflammation, oxidative stress and cholesterol accumulation. obeticholic acid 102-118 nuclear receptor subfamily 1, group H, member 4 Mus musculus 89-92 27940481-2 2017 Obeticholic acid (OCA) is a FXR agonist being developed for treating various chronic liver diseases. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 28-31 28130067-5 2017 Mice were gavaged with the FXR agonist obeticholic acid or vehicle for 11 days. obeticholic acid 39-55 nuclear receptor subfamily 1, group H, member 4 Mus musculus 27-30 28130067-10 2017 RESULTS: In livers of control mice and primary rat hepatocytes, activation of FXR with obeticholic acid increased expression of proteins that regulate amino acid degradation, ureagenesis, and glutamine synthesis. obeticholic acid 87-103 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 78-81 28115235-0 2017 Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis. obeticholic acid 74-90 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 62-65 28115235-1 2017 Farnesoid X receptor (FXR) activation by obeticholic acid (OCA) has been demonstrated to inhibit inflammation and fibrosis development in liver, kidney and intestine in multiple disease models. obeticholic acid 41-57 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 22-25 28115235-1 2017 Farnesoid X receptor (FXR) activation by obeticholic acid (OCA) has been demonstrated to inhibit inflammation and fibrosis development in liver, kidney and intestine in multiple disease models. obeticholic acid 59-62 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 22-25 27939613-2 2017 Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, shows promise in NASH trials. obeticholic acid 0-16 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 36-46 27939613-2 2017 Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, shows promise in NASH trials. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 48-51 27939613-2 2017 Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, shows promise in NASH trials. obeticholic acid 18-21 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 36-46 27939613-2 2017 Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, shows promise in NASH trials. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 48-51 27940481-2 2017 Obeticholic acid (OCA) is a FXR agonist being developed for treating various chronic liver diseases. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 28-31 27942596-9 2016 Consistent with clinical trial data, 0.5 muM obeticholic acid in this model promoted a healthy lipidomic signature, reduced inflammatory and fibrotic secreted factors, but also increased ApoB secretion, suggesting a potential adverse effect on lipoprotein metabolism. obeticholic acid 45-61 apolipoprotein B Homo sapiens 187-191 28468009-4 2017 Obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second-line therapy in PBC and has been recently licensed by the Food and Drug Administration and European Medicines Agency for use in patients showing an inadequate response to UDCA or who are unable to tolerate it. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 28-48 28468009-4 2017 Obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second-line therapy in PBC and has been recently licensed by the Food and Drug Administration and European Medicines Agency for use in patients showing an inadequate response to UDCA or who are unable to tolerate it. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 50-53 28468009-4 2017 Obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second-line therapy in PBC and has been recently licensed by the Food and Drug Administration and European Medicines Agency for use in patients showing an inadequate response to UDCA or who are unable to tolerate it. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 28-48 28468009-4 2017 Obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second-line therapy in PBC and has been recently licensed by the Food and Drug Administration and European Medicines Agency for use in patients showing an inadequate response to UDCA or who are unable to tolerate it. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 50-53 27425465-0 2017 Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension. obeticholic acid 64-80 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 52-55 27425465-1 2017 Farnesoid X receptor (FXR) activation by obeticholic acid (OCA) has been demonstrated to inhibit inflammation and fibrosis development and even induce fibrosis regression in liver, kidney and intestine in multiple disease models. obeticholic acid 41-57 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 22-25 27425465-1 2017 Farnesoid X receptor (FXR) activation by obeticholic acid (OCA) has been demonstrated to inhibit inflammation and fibrosis development and even induce fibrosis regression in liver, kidney and intestine in multiple disease models. obeticholic acid 59-62 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 22-25 28060943-2 2017 Since intestinal ischemia reperfusion injury (IRI) is characterized by hyperpermeability, bacterial translocation and inflammation, we aimed to investigate, for the first time, if the FXR-agonist obeticholic acid (OCA) could attenuate intestinal ischemia reperfusion injury. obeticholic acid 196-212 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 184-187 28060943-2 2017 Since intestinal ischemia reperfusion injury (IRI) is characterized by hyperpermeability, bacterial translocation and inflammation, we aimed to investigate, for the first time, if the FXR-agonist obeticholic acid (OCA) could attenuate intestinal ischemia reperfusion injury. obeticholic acid 214-217 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 184-187 27865854-2 2017 The aim of the present study was to investigate the effects of obeticholic acid (OCA), a novel synthetic FXR agonist, carbon tetrachloride (CCl4)-induced acute liver injury. obeticholic acid 63-79 nuclear receptor subfamily 1, group H, member 4 Mus musculus 105-108 27865854-2 2017 The aim of the present study was to investigate the effects of obeticholic acid (OCA), a novel synthetic FXR agonist, carbon tetrachloride (CCl4)-induced acute liver injury. obeticholic acid 63-79 chemokine (C-C motif) ligand 4 Mus musculus 140-144 27865854-2 2017 The aim of the present study was to investigate the effects of obeticholic acid (OCA), a novel synthetic FXR agonist, carbon tetrachloride (CCl4)-induced acute liver injury. obeticholic acid 81-84 nuclear receptor subfamily 1, group H, member 4 Mus musculus 105-108 27865854-2 2017 The aim of the present study was to investigate the effects of obeticholic acid (OCA), a novel synthetic FXR agonist, carbon tetrachloride (CCl4)-induced acute liver injury. obeticholic acid 81-84 chemokine (C-C motif) ligand 4 Mus musculus 140-144 27758768-3 2016 In this study, we show that FXR is present in human platelets and FXR ligands, GW4064 and 6alpha-ethyl-chenodeoxycholic acid, modulate platelet activation nongenomically. obeticholic acid 90-124 nuclear receptor subfamily 1 group H member 4 Homo sapiens 28-31 27758768-3 2016 In this study, we show that FXR is present in human platelets and FXR ligands, GW4064 and 6alpha-ethyl-chenodeoxycholic acid, modulate platelet activation nongenomically. obeticholic acid 90-124 nuclear receptor subfamily 1 group H member 4 Homo sapiens 66-69 27743502-1 2016 Obeticholic acid (OCA), a semisynthetic bile acid, is a selective and potent farnesoid X receptor (FXR) agonist in development for the treatment of chronic nonviral liver diseases. obeticholic acid 0-16 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 87-97 27743502-1 2016 Obeticholic acid (OCA), a semisynthetic bile acid, is a selective and potent farnesoid X receptor (FXR) agonist in development for the treatment of chronic nonviral liver diseases. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 99-102 27743502-1 2016 Obeticholic acid (OCA), a semisynthetic bile acid, is a selective and potent farnesoid X receptor (FXR) agonist in development for the treatment of chronic nonviral liver diseases. obeticholic acid 18-21 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 87-97 27743502-1 2016 Obeticholic acid (OCA), a semisynthetic bile acid, is a selective and potent farnesoid X receptor (FXR) agonist in development for the treatment of chronic nonviral liver diseases. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 99-102 27475255-3 2016 AIM OF THIS STUDY: to evaluate the efficacy of selective agonists INT747/obeticholic acid (FXR) and INT777 (TGR5) as novel treatments for the metabolic effects of oestrogen deficiency. obeticholic acid 73-89 nuclear receptor subfamily 1, group H, member 4 Mus musculus 91-94 27804232-0 2017 Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. obeticholic acid 0-16 WD and tetratricopeptide repeats 1 Mus musculus 26-33 27409173-6 2016 Exposure of MKN45 cells to GPBAR1 ligands, TLCA, oleanolic acid or 6-ECDCA (a dual FXR and GPBAR1 ligand) increased the expression of genes associated with EMT including KDKN2A, HRAS, IGB3, MMP10 and MMP13 and downregulated the expression of CD44 and FAT1 (P<0.01 versus control cells). obeticholic acid 67-74 G protein-coupled bile acid receptor 1 Homo sapiens 27-33 27634375-3 2016 We investigated preventive and therapeutic effects of FXR agonist obeticholic acid (OCA) on hepatic inflammation and fibrosis in toxic cirrhotic rats. obeticholic acid 84-87 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 54-57 27589928-2 2016 Obeticholic Acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second line therapy in PBC and has recently been licenced by the FDA. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 28-48 27589928-2 2016 Obeticholic Acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second line therapy in PBC and has recently been licenced by the FDA. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 50-53 27589928-2 2016 Obeticholic Acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second line therapy in PBC and has recently been licenced by the FDA. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 28-48 27589928-2 2016 Obeticholic Acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second line therapy in PBC and has recently been licenced by the FDA. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 50-53 27359351-3 2016 Here, we show that the FXR agonist, obeticholic acid (OCA), increases fecal cholesterol excretion and macrophage reverse cholesterol transport (RCT) dependent on activation of hepatic FXR. obeticholic acid 36-52 nuclear receptor subfamily 1, group H, member 4 Mus musculus 23-26 27359351-3 2016 Here, we show that the FXR agonist, obeticholic acid (OCA), increases fecal cholesterol excretion and macrophage reverse cholesterol transport (RCT) dependent on activation of hepatic FXR. obeticholic acid 36-52 nuclear receptor subfamily 1, group H, member 4 Mus musculus 184-187 27359351-3 2016 Here, we show that the FXR agonist, obeticholic acid (OCA), increases fecal cholesterol excretion and macrophage reverse cholesterol transport (RCT) dependent on activation of hepatic FXR. obeticholic acid 54-57 nuclear receptor subfamily 1, group H, member 4 Mus musculus 23-26 27359351-3 2016 Here, we show that the FXR agonist, obeticholic acid (OCA), increases fecal cholesterol excretion and macrophage reverse cholesterol transport (RCT) dependent on activation of hepatic FXR. obeticholic acid 54-57 nuclear receptor subfamily 1, group H, member 4 Mus musculus 184-187 27409173-6 2016 Exposure of MKN45 cells to GPBAR1 ligands, TLCA, oleanolic acid or 6-ECDCA (a dual FXR and GPBAR1 ligand) increased the expression of genes associated with EMT including KDKN2A, HRAS, IGB3, MMP10 and MMP13 and downregulated the expression of CD44 and FAT1 (P<0.01 versus control cells). obeticholic acid 67-74 nuclear receptor subfamily 1 group H member 4 Homo sapiens 83-86 27409173-6 2016 Exposure of MKN45 cells to GPBAR1 ligands, TLCA, oleanolic acid or 6-ECDCA (a dual FXR and GPBAR1 ligand) increased the expression of genes associated with EMT including KDKN2A, HRAS, IGB3, MMP10 and MMP13 and downregulated the expression of CD44 and FAT1 (P<0.01 versus control cells). obeticholic acid 67-74 G protein-coupled bile acid receptor 1 Homo sapiens 91-97 27409173-6 2016 Exposure of MKN45 cells to GPBAR1 ligands, TLCA, oleanolic acid or 6-ECDCA (a dual FXR and GPBAR1 ligand) increased the expression of genes associated with EMT including KDKN2A, HRAS, IGB3, MMP10 and MMP13 and downregulated the expression of CD44 and FAT1 (P<0.01 versus control cells). obeticholic acid 67-74 HRas proto-oncogene, GTPase Homo sapiens 178-182 27409173-6 2016 Exposure of MKN45 cells to GPBAR1 ligands, TLCA, oleanolic acid or 6-ECDCA (a dual FXR and GPBAR1 ligand) increased the expression of genes associated with EMT including KDKN2A, HRAS, IGB3, MMP10 and MMP13 and downregulated the expression of CD44 and FAT1 (P<0.01 versus control cells). obeticholic acid 67-74 matrix metallopeptidase 10 Homo sapiens 190-195 27409173-6 2016 Exposure of MKN45 cells to GPBAR1 ligands, TLCA, oleanolic acid or 6-ECDCA (a dual FXR and GPBAR1 ligand) increased the expression of genes associated with EMT including KDKN2A, HRAS, IGB3, MMP10 and MMP13 and downregulated the expression of CD44 and FAT1 (P<0.01 versus control cells). obeticholic acid 67-74 matrix metallopeptidase 13 Homo sapiens 200-205 27409173-6 2016 Exposure of MKN45 cells to GPBAR1 ligands, TLCA, oleanolic acid or 6-ECDCA (a dual FXR and GPBAR1 ligand) increased the expression of genes associated with EMT including KDKN2A, HRAS, IGB3, MMP10 and MMP13 and downregulated the expression of CD44 and FAT1 (P<0.01 versus control cells). obeticholic acid 67-74 CD44 molecule (Indian blood group) Homo sapiens 242-246 27409173-6 2016 Exposure of MKN45 cells to GPBAR1 ligands, TLCA, oleanolic acid or 6-ECDCA (a dual FXR and GPBAR1 ligand) increased the expression of genes associated with EMT including KDKN2A, HRAS, IGB3, MMP10 and MMP13 and downregulated the expression of CD44 and FAT1 (P<0.01 versus control cells). obeticholic acid 67-74 FAT atypical cadherin 1 Homo sapiens 251-255 27251172-4 2016 In HepaRG cells, FXR agonists (6-ethyl chenodeoxycholic acid and GW4064), but no antagonist, and an FXR-unrelated bile salt inhibited viral mRNA, DNA, and protein production (IC50, 0.1-0.5 muM) and reduced covalently closed circular DNA pool size. obeticholic acid 31-60 nuclear receptor subfamily 1 group H member 4 Homo sapiens 17-20 27468093-14 2016 Six-ethyl chenodeoxycholic acid (6-ECDCA), a potent farnesoid X receptor (FXR) agonist, has shown anti-cholestatic activity in rodent models of cholestasis. obeticholic acid 33-40 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 62-72 27468093-14 2016 Six-ethyl chenodeoxycholic acid (6-ECDCA), a potent farnesoid X receptor (FXR) agonist, has shown anti-cholestatic activity in rodent models of cholestasis. obeticholic acid 33-40 nuclear receptor subfamily 1 group H member 4 Homo sapiens 74-77 27468093-15 2016 Obeticholic acid (OCA, 6-ECDCA, or INT-747), a first-in-class FXR agonist, has been examined in PBC patients with inadequate response to UDCA, and shown promising results. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 62-65 27406083-1 2016 Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 36-56 27109453-1 2016 The bile acid analogue obeticholic acid (OCA) is a selective farnesoid X receptor (FXR) agonist in development for treatment of several chronic liver diseases. obeticholic acid 23-39 nuclear receptor subfamily 1 group H member 4 Homo sapiens 61-81 27109453-1 2016 The bile acid analogue obeticholic acid (OCA) is a selective farnesoid X receptor (FXR) agonist in development for treatment of several chronic liver diseases. obeticholic acid 23-39 nuclear receptor subfamily 1 group H member 4 Homo sapiens 83-86 27406083-1 2016 Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 58-61 27406083-1 2016 Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. obeticholic acid 18-25 nuclear receptor subfamily 1 group H member 4 Homo sapiens 36-56 27406083-1 2016 Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. obeticholic acid 18-25 nuclear receptor subfamily 1 group H member 4 Homo sapiens 58-61 27255380-8 2016 Moreover, treatment with the FXR agonist obeticholic acid (OCA) generated obvious reductions in serum ALT, AST, and TBA levels in PZA-treated rats. obeticholic acid 41-57 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 29-32 27255380-8 2016 Moreover, treatment with the FXR agonist obeticholic acid (OCA) generated obvious reductions in serum ALT, AST, and TBA levels in PZA-treated rats. obeticholic acid 59-62 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 29-32 26812075-0 2016 Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid. obeticholic acid 93-109 nuclear receptor subfamily 1 group H member 4 Homo sapiens 81-84 30695468-11 2016 Among recently developed drugs, farnesoid X nuclear receptor ligand obeticholic acid is the most promising for first-in-class treatment of NASH. obeticholic acid 68-84 nuclear receptor subfamily 1 group H member 4 Homo sapiens 32-60 26812075-2 2016 Obeticholic acid (OCA), a promising drug for the treatment of non-alcoholic steatohepatitis (NASH) and type 2 diabetes, activates FXR. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 130-133 26812075-2 2016 Obeticholic acid (OCA), a promising drug for the treatment of non-alcoholic steatohepatitis (NASH) and type 2 diabetes, activates FXR. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 130-133 26811456-5 2016 Obeticholic acid (6alpha-ethyl-chenodeoxycholic acid, 6-ECDCA), a synthetic FXR agonist, is an orally available drug that is currently in clinical trials for the treatment of inflammatory diseases such as alcoholic hepatitis, nonalcoholic steatohepatitis, and primary biliary cirrhosis. obeticholic acid 0-16 nuclear receptor subfamily 1, group H, member 4 Mus musculus 76-79 26811456-5 2016 Obeticholic acid (6alpha-ethyl-chenodeoxycholic acid, 6-ECDCA), a synthetic FXR agonist, is an orally available drug that is currently in clinical trials for the treatment of inflammatory diseases such as alcoholic hepatitis, nonalcoholic steatohepatitis, and primary biliary cirrhosis. obeticholic acid 18-52 nuclear receptor subfamily 1, group H, member 4 Mus musculus 76-79 26811456-5 2016 Obeticholic acid (6alpha-ethyl-chenodeoxycholic acid, 6-ECDCA), a synthetic FXR agonist, is an orally available drug that is currently in clinical trials for the treatment of inflammatory diseases such as alcoholic hepatitis, nonalcoholic steatohepatitis, and primary biliary cirrhosis. obeticholic acid 54-61 nuclear receptor subfamily 1, group H, member 4 Mus musculus 76-79 26554605-5 2016 We show that FXR activation by obeticholic acid (OCA) has systemic anti-inflammatory effects that include increased levels of plasma IL-10, inhibition of both DSS-colitis associated decrease in splenic dendritic cells (DCs) and increase in Tregs. obeticholic acid 31-47 nuclear receptor subfamily 1 group H member 4 Homo sapiens 13-16 26554605-5 2016 We show that FXR activation by obeticholic acid (OCA) has systemic anti-inflammatory effects that include increased levels of plasma IL-10, inhibition of both DSS-colitis associated decrease in splenic dendritic cells (DCs) and increase in Tregs. obeticholic acid 31-47 interleukin 10 Homo sapiens 133-138 26870934-7 2016 Other novel key players represent the nuclear bile acid receptor farnesoid X receptor (FXR; targeted by synthetic FXR ligands such as obeticholic acid) and RAR-related orphan receptor gamma two (RORgammat). obeticholic acid 134-150 nuclear receptor subfamily 1 group H member 4 Homo sapiens 87-90 26870934-7 2016 Other novel key players represent the nuclear bile acid receptor farnesoid X receptor (FXR; targeted by synthetic FXR ligands such as obeticholic acid) and RAR-related orphan receptor gamma two (RORgammat). obeticholic acid 134-150 nuclear receptor subfamily 1 group H member 4 Homo sapiens 114-117 26655953-6 2016 In mice treated with the FXR agonist obeticholic acid, renal injury, renal lipid accumulation, apoptosis, and changes in lipid peroxidation were attenuated. obeticholic acid 37-53 nuclear receptor subfamily 1, group H, member 4 Mus musculus 25-28 25864227-0 2015 Obeticholic acid: expanding the therapeutic landscape of NASH. obeticholic acid 0-16 SAM domain, SH3 domain and nuclear localization signals 1 Homo sapiens 57-61 26320013-5 2015 Early human data using a FXR agonist, obeticholic acid, have shown promising results with improvement of histological activity and even a reduction of fibrosis. obeticholic acid 38-54 nuclear receptor subfamily 1 group H member 4 Homo sapiens 25-28 26177448-6 2015 RESULTS: In naive mice skin application of DCA, TLCA, 6-ECDCA, oleanolic and betulinic acid induces a GPBAR1 dependent pruritogenic response that could be desensitized by re-challenging the mice with the same GPBAR1 agonist. obeticholic acid 54-61 G protein-coupled bile acid receptor 1 Mus musculus 102-108 26177448-6 2015 RESULTS: In naive mice skin application of DCA, TLCA, 6-ECDCA, oleanolic and betulinic acid induces a GPBAR1 dependent pruritogenic response that could be desensitized by re-challenging the mice with the same GPBAR1 agonist. obeticholic acid 54-61 G protein-coupled bile acid receptor 1 Mus musculus 209-215 26114083-7 2015 The farnesoid X nuclear receptor (FXR) has been demonstrated to have important metabolic effects and its pharmacological activation by obeticholic acid has been recently reported to produce histological improvement in NASH. obeticholic acid 135-151 nuclear receptor subfamily 1 group H member 4 Homo sapiens 4-32 26114083-7 2015 The farnesoid X nuclear receptor (FXR) has been demonstrated to have important metabolic effects and its pharmacological activation by obeticholic acid has been recently reported to produce histological improvement in NASH. obeticholic acid 135-151 nuclear receptor subfamily 1 group H member 4 Homo sapiens 34-37 26114083-7 2015 The farnesoid X nuclear receptor (FXR) has been demonstrated to have important metabolic effects and its pharmacological activation by obeticholic acid has been recently reported to produce histological improvement in NASH. obeticholic acid 135-151 SAM domain, SH3 domain and nuclear localization signals 1 Homo sapiens 218-222 27170389-8 2016 Recent clinical trials have revealed a beneficial impact of the FXR agonist obeticholic acid on body weight, insulin sensitivity and liver histology in patients with NASH. obeticholic acid 76-92 nuclear receptor subfamily 1 group H member 4 Homo sapiens 64-67 26549695-3 2016 Obeticholic acid (OCA) is a potent ligand of the nuclear hormone receptor farnesoid X receptor (FXR). obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 96-99 26549695-3 2016 Obeticholic acid (OCA) is a potent ligand of the nuclear hormone receptor farnesoid X receptor (FXR). obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 96-99 26052375-12 2015 Obeticholic acid is a potent activator of the farnesoid X nuclear receptor and reduces liver fat content and fibrosis in animal models. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 46-74 25926979-6 2015 Recently, the FLINT (Farnesoid X Receptor [FXR] Ligand Obeticholic Acid in NASH Treatment) trial provided promising results of the efficacy of obeticholic acid, a farnesoid X receptor agonist, in improving histological features of NASH and fibrosis. obeticholic acid 55-71 nuclear receptor subfamily 1 group H member 4 Homo sapiens 21-41 25468160-0 2015 Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. obeticholic acid 36-52 nuclear receptor subfamily 1 group H member 4 Homo sapiens 0-28 25468160-1 2015 BACKGROUND: The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. obeticholic acid 37-65 nuclear receptor subfamily 1 group H member 4 Homo sapiens 114-142 25468160-1 2015 BACKGROUND: The bile acid derivative 6-ethylchenodeoxycholic acid (obeticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and fibrosis in animal models of fatty liver disease. obeticholic acid 67-83 nuclear receptor subfamily 1 group H member 4 Homo sapiens 114-142 25926979-6 2015 Recently, the FLINT (Farnesoid X Receptor [FXR] Ligand Obeticholic Acid in NASH Treatment) trial provided promising results of the efficacy of obeticholic acid, a farnesoid X receptor agonist, in improving histological features of NASH and fibrosis. obeticholic acid 55-71 nuclear receptor subfamily 1 group H member 4 Homo sapiens 43-46 25926979-6 2015 Recently, the FLINT (Farnesoid X Receptor [FXR] Ligand Obeticholic Acid in NASH Treatment) trial provided promising results of the efficacy of obeticholic acid, a farnesoid X receptor agonist, in improving histological features of NASH and fibrosis. obeticholic acid 55-71 nuclear receptor subfamily 1 group H member 4 Homo sapiens 163-183 25926979-6 2015 Recently, the FLINT (Farnesoid X Receptor [FXR] Ligand Obeticholic Acid in NASH Treatment) trial provided promising results of the efficacy of obeticholic acid, a farnesoid X receptor agonist, in improving histological features of NASH and fibrosis. obeticholic acid 143-159 nuclear receptor subfamily 1 group H member 4 Homo sapiens 21-41 25926979-6 2015 Recently, the FLINT (Farnesoid X Receptor [FXR] Ligand Obeticholic Acid in NASH Treatment) trial provided promising results of the efficacy of obeticholic acid, a farnesoid X receptor agonist, in improving histological features of NASH and fibrosis. obeticholic acid 143-159 nuclear receptor subfamily 1 group H member 4 Homo sapiens 43-46 25926979-6 2015 Recently, the FLINT (Farnesoid X Receptor [FXR] Ligand Obeticholic Acid in NASH Treatment) trial provided promising results of the efficacy of obeticholic acid, a farnesoid X receptor agonist, in improving histological features of NASH and fibrosis. obeticholic acid 143-159 nuclear receptor subfamily 1 group H member 4 Homo sapiens 163-183 25152204-6 2015 Subsequently, sham-operated or bile-duct-ligated (BDL) cirrhosis rats were treated with the FXR agonist obeticholic acid (OA, 5 mg/kg) or vehicle for 5 days. obeticholic acid 104-120 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 92-95 25592258-0 2015 The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. obeticholic acid 16-32 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 4-7 25329562-0 2015 The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. obeticholic acid 86-102 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 67-77 25329562-3 2015 AIM: To investigate whether obeticholic acid, a potent FXR agonist, could increase FGF19 in patients with bile acid diarrhoea, and produce clinical benefits. obeticholic acid 28-44 nuclear receptor subfamily 1 group H member 4 Homo sapiens 55-58 25329562-3 2015 AIM: To investigate whether obeticholic acid, a potent FXR agonist, could increase FGF19 in patients with bile acid diarrhoea, and produce clinical benefits. obeticholic acid 28-44 fibroblast growth factor 19 Homo sapiens 83-88 25329562-6 2015 RESULTS: In primary bile acid diarrhoea, obeticholic acid increased median fasting FGF19 (133-237 pg/mL, P = 0.007) and significantly reduced fasting C4 and bile acid responses. obeticholic acid 41-57 fibroblast growth factor 19 Homo sapiens 83-88 25329562-13 2015 CONCLUSIONS: This proof-of-concept study indicates that obeticholic acid stimulates FGF19, reduces bile acid synthesis and produces clinical benefits in bile acid diarrhoea. obeticholic acid 56-72 fibroblast growth factor 19 Homo sapiens 84-89 25705637-8 2015 Obeticholic acid (OCA), a 6alpha-ethyl derivative of the natural human BA chenodeoxycholic acid (CDCA) is the first-in-class selective FXR agonist that is ~100-fold more potent than CDCA. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 135-138 25705637-8 2015 Obeticholic acid (OCA), a 6alpha-ethyl derivative of the natural human BA chenodeoxycholic acid (CDCA) is the first-in-class selective FXR agonist that is ~100-fold more potent than CDCA. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 135-138 26642350-10 2015 The effect of new agents such obeticholic acid are promising, since the addition of this farnesoide-X-receptor agonist bile acid in patients with stable UDCA dosage and increased alkaline phosphatase levels results in an improvement of cholestasis as compared to placebo, with a parallel decrease of aminotransferases and immunoglobulin M, as well as one surrogate marker of bile acid synthesis. obeticholic acid 30-46 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 100-110 24475141-2 2014 We investigated whether 6-ethyl chenodeoxycholic acid (6ECDCA), a semisynthetic derivative of chenodeoxycholic aicd (CDCA, an FXR ligand), protects against kidney injury and modulates small heterodimer partner (SHP) in cisplatin-induced kidney injury. obeticholic acid 55-61 nuclear receptor subfamily 0, group B, member 2 Mus musculus 211-214 25200104-4 2014 AREAS COVERED: The semisynthetic bile acid derivative 6-ethyl chenodeoxycholic acid (6-ECDCA, INT-747 later christened obeticholic acid) is a dual FXR/GP-BAR1 ligand that attenuates bile flow impairment in cholestasis induced by 17beta-estradiol; a model of pregnancy-induced cholestasis. obeticholic acid 54-83 nuclear receptor subfamily 1 group H member 4 Homo sapiens 147-150 25200104-4 2014 AREAS COVERED: The semisynthetic bile acid derivative 6-ethyl chenodeoxycholic acid (6-ECDCA, INT-747 later christened obeticholic acid) is a dual FXR/GP-BAR1 ligand that attenuates bile flow impairment in cholestasis induced by 17beta-estradiol; a model of pregnancy-induced cholestasis. obeticholic acid 54-83 G protein-coupled bile acid receptor 1 Homo sapiens 151-158 25200104-4 2014 AREAS COVERED: The semisynthetic bile acid derivative 6-ethyl chenodeoxycholic acid (6-ECDCA, INT-747 later christened obeticholic acid) is a dual FXR/GP-BAR1 ligand that attenuates bile flow impairment in cholestasis induced by 17beta-estradiol; a model of pregnancy-induced cholestasis. obeticholic acid 85-92 nuclear receptor subfamily 1 group H member 4 Homo sapiens 147-150 25200104-4 2014 AREAS COVERED: The semisynthetic bile acid derivative 6-ethyl chenodeoxycholic acid (6-ECDCA, INT-747 later christened obeticholic acid) is a dual FXR/GP-BAR1 ligand that attenuates bile flow impairment in cholestasis induced by 17beta-estradiol; a model of pregnancy-induced cholestasis. obeticholic acid 85-92 G protein-coupled bile acid receptor 1 Homo sapiens 151-158 25200104-4 2014 AREAS COVERED: The semisynthetic bile acid derivative 6-ethyl chenodeoxycholic acid (6-ECDCA, INT-747 later christened obeticholic acid) is a dual FXR/GP-BAR1 ligand that attenuates bile flow impairment in cholestasis induced by 17beta-estradiol; a model of pregnancy-induced cholestasis. obeticholic acid 119-135 nuclear receptor subfamily 1 group H member 4 Homo sapiens 147-150 25200104-4 2014 AREAS COVERED: The semisynthetic bile acid derivative 6-ethyl chenodeoxycholic acid (6-ECDCA, INT-747 later christened obeticholic acid) is a dual FXR/GP-BAR1 ligand that attenuates bile flow impairment in cholestasis induced by 17beta-estradiol; a model of pregnancy-induced cholestasis. obeticholic acid 119-135 G protein-coupled bile acid receptor 1 Homo sapiens 151-158 24382005-5 2014 In particular, obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist that has an important role in the enterohepatic circulation of BAs. obeticholic acid 15-31 nuclear receptor subfamily 1 group H member 4 Homo sapiens 65-68 24382005-5 2014 In particular, obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist that has an important role in the enterohepatic circulation of BAs. obeticholic acid 33-36 nuclear receptor subfamily 1 group H member 4 Homo sapiens 43-63 24382005-5 2014 In particular, obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist that has an important role in the enterohepatic circulation of BAs. obeticholic acid 33-36 nuclear receptor subfamily 1 group H member 4 Homo sapiens 65-68 24475141-2 2014 We investigated whether 6-ethyl chenodeoxycholic acid (6ECDCA), a semisynthetic derivative of chenodeoxycholic aicd (CDCA, an FXR ligand), protects against kidney injury and modulates small heterodimer partner (SHP) in cisplatin-induced kidney injury. obeticholic acid 24-53 nuclear receptor subfamily 1, group H, member 4 Mus musculus 126-129 24475141-2 2014 We investigated whether 6-ethyl chenodeoxycholic acid (6ECDCA), a semisynthetic derivative of chenodeoxycholic aicd (CDCA, an FXR ligand), protects against kidney injury and modulates small heterodimer partner (SHP) in cisplatin-induced kidney injury. obeticholic acid 24-53 nuclear receptor subfamily 0, group B, member 2 Mus musculus 211-214 24475141-2 2014 We investigated whether 6-ethyl chenodeoxycholic acid (6ECDCA), a semisynthetic derivative of chenodeoxycholic aicd (CDCA, an FXR ligand), protects against kidney injury and modulates small heterodimer partner (SHP) in cisplatin-induced kidney injury. obeticholic acid 55-61 nuclear receptor subfamily 1, group H, member 4 Mus musculus 126-129 24713361-0 2014 The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. obeticholic acid 16-22 nuclear receptor subfamily 1, group H, member 4 Mus musculus 4-7 24713361-2 2014 Since the FXR receptor regulates adipose cell function and liver lipid metabolism, the aim of this work was to examine the effects of the FXR agonist 6ECDCA on alcoholic liver steatosis development and on oxidative stress induced by ethanol consumption. obeticholic acid 150-156 nuclear receptor subfamily 1, group H, member 4 Mus musculus 10-13 24713361-2 2014 Since the FXR receptor regulates adipose cell function and liver lipid metabolism, the aim of this work was to examine the effects of the FXR agonist 6ECDCA on alcoholic liver steatosis development and on oxidative stress induced by ethanol consumption. obeticholic acid 150-156 nuclear receptor subfamily 1, group H, member 4 Mus musculus 138-141 24475141-8 2014 In conclusion, FXR ligand, 6ECDCA prevents cisplatin-induced kidney injury, the underlying mechanism of which may be associated with anti-fibrotic, anti-inflammatory, and anti-apoptotic effects through SHP induction. obeticholic acid 27-33 nuclear receptor subfamily 1, group H, member 4 Mus musculus 15-18 24475141-8 2014 In conclusion, FXR ligand, 6ECDCA prevents cisplatin-induced kidney injury, the underlying mechanism of which may be associated with anti-fibrotic, anti-inflammatory, and anti-apoptotic effects through SHP induction. obeticholic acid 27-33 nuclear receptor subfamily 0, group B, member 2 Mus musculus 202-205 23518683-12 2013 The synthetic FXR agonist obeticholic acid was much more potent than CDCA with a 70-fold FGF19 stimulation at 1 muM. obeticholic acid 26-42 nuclear receptor subfamily 1 group H member 4 Homo sapiens 14-17 24382005-5 2014 In particular, obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist that has an important role in the enterohepatic circulation of BAs. obeticholic acid 15-31 nuclear receptor subfamily 1 group H member 4 Homo sapiens 43-63 25388536-1 2014 The Farnesoid X Receptor (FXR) was recently validated in clinical studies using the bile acid analogue Obeticholic Acid (OCA) as an attractive drug target for liver diseases such as Primary Biliary Cirrhosis (PBC) or Non-alcoholic Steatohepatitis (NASH). obeticholic acid 103-119 nuclear receptor subfamily 1 group H member 4 Homo sapiens 4-24 25388536-1 2014 The Farnesoid X Receptor (FXR) was recently validated in clinical studies using the bile acid analogue Obeticholic Acid (OCA) as an attractive drug target for liver diseases such as Primary Biliary Cirrhosis (PBC) or Non-alcoholic Steatohepatitis (NASH). obeticholic acid 103-119 nuclear receptor subfamily 1 group H member 4 Homo sapiens 26-29 23609136-10 2013 In vitro, activation of FXR by bile acids (chenodeoxycholic acid [CDCA] or 6-ECDCA) or FXR agonists (GW4064 or Fexaramine) significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal-regulated kinase (ERK) and beta-catenin signaling. obeticholic acid 75-82 nuclear receptor subfamily 1, group H, member 4 Mus musculus 24-27 23518683-12 2013 The synthetic FXR agonist obeticholic acid was much more potent than CDCA with a 70-fold FGF19 stimulation at 1 muM. obeticholic acid 26-42 fibroblast growth factor 19 Homo sapiens 89-94 23518683-12 2013 The synthetic FXR agonist obeticholic acid was much more potent than CDCA with a 70-fold FGF19 stimulation at 1 muM. obeticholic acid 26-42 latexin Homo sapiens 112-115 21707532-0 2011 Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. obeticholic acid 90-102 nuclear receptor subfamily 1 group H member 4 Homo sapiens 0-20 22999992-0 2012 An improved synthesis of 6alpha-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR). obeticholic acid 25-58 nuclear receptor subfamily 1 group H member 4 Homo sapiens 108-128 22999992-0 2012 An improved synthesis of 6alpha-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR). obeticholic acid 25-58 nuclear receptor subfamily 1 group H member 4 Homo sapiens 130-133 22999992-0 2012 An improved synthesis of 6alpha-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR). obeticholic acid 60-66 nuclear receptor subfamily 1 group H member 4 Homo sapiens 108-128 22999992-0 2012 An improved synthesis of 6alpha-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR). obeticholic acid 60-66 nuclear receptor subfamily 1 group H member 4 Homo sapiens 130-133 22999992-1 2012 The active, potent, and selective Farnesoid X Receptor (FXR) agonist 6alpha-ethylchenodeoxycholic acid (6ECDCA) has been synthesized in improved yield compared to the published methodologies. obeticholic acid 69-102 nuclear receptor subfamily 1 group H member 4 Homo sapiens 34-54 22999992-1 2012 The active, potent, and selective Farnesoid X Receptor (FXR) agonist 6alpha-ethylchenodeoxycholic acid (6ECDCA) has been synthesized in improved yield compared to the published methodologies. obeticholic acid 69-102 nuclear receptor subfamily 1 group H member 4 Homo sapiens 56-59 22999992-1 2012 The active, potent, and selective Farnesoid X Receptor (FXR) agonist 6alpha-ethylchenodeoxycholic acid (6ECDCA) has been synthesized in improved yield compared to the published methodologies. obeticholic acid 104-110 nuclear receptor subfamily 1 group H member 4 Homo sapiens 34-54 22999992-1 2012 The active, potent, and selective Farnesoid X Receptor (FXR) agonist 6alpha-ethylchenodeoxycholic acid (6ECDCA) has been synthesized in improved yield compared to the published methodologies. obeticholic acid 104-110 nuclear receptor subfamily 1 group H member 4 Homo sapiens 56-59 23141888-5 2012 Encouraging data from recent experimental and phase-II studies tend to confirm that the FXR agonist obeticholic acid and the PPARalpha agonists bezafibrate and fenofibrate may be used as add-on therapies in PBC patients with inadequate responses to UDCA or even as alternative first-line agents. obeticholic acid 100-116 nuclear receptor subfamily 1 group H member 4 Homo sapiens 88-91 23141891-4 2012 Obeticholic acid is a bile-acid mimetic, with no toxic or inflammagen behavior, that strongly activates FXR to combat the toxic effects of high concentrations of bile acid. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 104-107 22652341-4 2012 We also discuss the potential of the semi-synthetic BA derivative obeticholic acid (OCA), a first-in-class FXR agonist, as a safe and effective drug to address this significant unmet medical need. obeticholic acid 66-82 nuclear receptor subfamily 1 group H member 4 Homo sapiens 107-110 20014870-1 2009 In the framework of the design and development of TGR5 agonists, we reported that the introduction of a C(23)(S)-methyl group in the side chain of bile acids such as chenodeoxycholic acid (CDCA) and 6-ethylchenodeoxycholic acid (6-ECDCA, INT-747) affords selectivity for TGR5. obeticholic acid 199-227 G protein-coupled bile acid receptor 1 Homo sapiens 50-54 20431060-6 2010 FXR activation by a synthetic FXR agonist, 6alpha-ethyl chenodeoxycholic acid (INT-747) inhibited phosphate induced-mineralization and triglyceride accumulation in CVCs. obeticholic acid 43-77 nuclear receptor subfamily 1, group H, member 4 Mus musculus 0-3 20431060-6 2010 FXR activation by a synthetic FXR agonist, 6alpha-ethyl chenodeoxycholic acid (INT-747) inhibited phosphate induced-mineralization and triglyceride accumulation in CVCs. obeticholic acid 43-77 nuclear receptor subfamily 1, group H, member 4 Mus musculus 30-33 19783811-3 2010 In this study, we investigated the effect of FXR activation by 6-ethyl-chenodeoxycholic acid, (6E-CDCA, 10 mg/kg) on insulin resistance and liver and muscle lipid metabolism in fa/fa rats and compared its activity with rosiglitazone (10 mg/kg) alone or in combination with 6E-CDCA (5 mg/kg each). obeticholic acid 63-92 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 45-48 19783811-3 2010 In this study, we investigated the effect of FXR activation by 6-ethyl-chenodeoxycholic acid, (6E-CDCA, 10 mg/kg) on insulin resistance and liver and muscle lipid metabolism in fa/fa rats and compared its activity with rosiglitazone (10 mg/kg) alone or in combination with 6E-CDCA (5 mg/kg each). obeticholic acid 95-102 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 45-48 19783811-3 2010 In this study, we investigated the effect of FXR activation by 6-ethyl-chenodeoxycholic acid, (6E-CDCA, 10 mg/kg) on insulin resistance and liver and muscle lipid metabolism in fa/fa rats and compared its activity with rosiglitazone (10 mg/kg) alone or in combination with 6E-CDCA (5 mg/kg each). obeticholic acid 273-280 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 45-48 20014870-1 2009 In the framework of the design and development of TGR5 agonists, we reported that the introduction of a C(23)(S)-methyl group in the side chain of bile acids such as chenodeoxycholic acid (CDCA) and 6-ethylchenodeoxycholic acid (6-ECDCA, INT-747) affords selectivity for TGR5. obeticholic acid 199-227 G protein-coupled bile acid receptor 1 Homo sapiens 271-275 20014870-1 2009 In the framework of the design and development of TGR5 agonists, we reported that the introduction of a C(23)(S)-methyl group in the side chain of bile acids such as chenodeoxycholic acid (CDCA) and 6-ethylchenodeoxycholic acid (6-ECDCA, INT-747) affords selectivity for TGR5. obeticholic acid 229-236 G protein-coupled bile acid receptor 1 Homo sapiens 50-54 16178789-8 2005 The 6-ethyl derivative of CDCA (6-ECDCA) is approximately 100 fold more potent than CDCA in activating FXR in vitro. obeticholic acid 32-39 nuclear receptor subfamily 1 group H member 4 Homo sapiens 103-106 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 41-70 nuclear receptor subfamily 1, group H, member 4 Mus musculus 102-105 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 41-70 tumor necrosis factor Mus musculus 179-188 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 41-70 interleukin 1 beta Mus musculus 190-198 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 41-70 interleukin 6 Mus musculus 200-204 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 41-70 cytochrome c oxidase I, mitochondrial Mus musculus 206-211 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 41-70 cytochrome c oxidase II, mitochondrial Mus musculus 213-218 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 41-70 nitric oxide synthase 2, inducible Mus musculus 224-228 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 41-70 nuclear receptor subfamily 0, group B, member 2 Mus musculus 247-250 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 41-70 nuclear receptor subfamily 1, group H, member 4 Mus musculus 254-257 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 72-79 nuclear receptor subfamily 1, group H, member 4 Mus musculus 102-105 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 72-79 tumor necrosis factor Mus musculus 179-188 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 72-79 interleukin 1 beta Mus musculus 190-198 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 72-79 interleukin 6 Mus musculus 200-204 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 72-79 cytochrome c oxidase I, mitochondrial Mus musculus 206-211 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 72-79 cytochrome c oxidase II, mitochondrial Mus musculus 213-218 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 72-79 nitric oxide synthase 2, inducible Mus musculus 224-228 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 72-79 nuclear receptor subfamily 0, group B, member 2 Mus musculus 247-250 19864602-5 2009 Exposure of LPS-activated macrophages to 6-ethyl chenodeoxycholic acid (6E-CDCA; INT-747) a synthetic FXR ligand, results in a reciprocal regulation of NF-kappaB dependent-genes (TNF-alpha, IL-1beta, IL-6, COX-1, COX-2, and iNOS) and induction of SHP, a FXR-regulated gene. obeticholic acid 72-79 nuclear receptor subfamily 1, group H, member 4 Mus musculus 254-257 19418582-2 2009 METHODS: The regulation of CSE expression in response to FXR ligands was evaluated in HepG2 cells and in wild-type and FXR null mice treated with 6-ethyl chenodeoxycholic acid (6E-CDCA), a synthetic FXR ligand. obeticholic acid 177-184 nuclear receptor subfamily 1 group H member 4 Homo sapiens 57-60 16778009-5 2006 Exposure of 3T3-L1 cells to INT-747 (6-ethyl cheno-deoxycholic acid), a potent and selective FXR ligand, increases preadipocyte differentiation induced by a differentiating mixture containing insulin. obeticholic acid 37-67 nuclear receptor subfamily 1, group H, member 4 Mus musculus 93-96 19776172-5 2009 Treatment of these mice with the highly selective and potent FXR-activating ligand 6-alpha-ethyl-chenodeoxycholic acid (INT-747) ameliorates triglyceride accumulation by modulating fatty acid synthesis and oxidation, improves proteinuria, prevents podocyte loss, mesangial expansion, accumulation of extracellular matrix proteins, and increased expression of profibrotic growth factors and fibrosis markers, and modulates inflammation and oxidative stress. obeticholic acid 83-118 nuclear receptor subfamily 1, group H, member 4 Mus musculus 61-64 19027009-7 2009 FXR activity remained intact in these cells, as evidenced by 6alpha-ethyl chenodeoxycholic acid-mediated induction of small heterodimer partner, BSEP, and multidrug-resistant protein (MDR) 3/Mdr2. obeticholic acid 61-95 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 0-3 19027009-7 2009 FXR activity remained intact in these cells, as evidenced by 6alpha-ethyl chenodeoxycholic acid-mediated induction of small heterodimer partner, BSEP, and multidrug-resistant protein (MDR) 3/Mdr2. obeticholic acid 61-95 ATP binding cassette subfamily B member 11 Rattus norvegicus 145-149 19027009-7 2009 FXR activity remained intact in these cells, as evidenced by 6alpha-ethyl chenodeoxycholic acid-mediated induction of small heterodimer partner, BSEP, and multidrug-resistant protein (MDR) 3/Mdr2. obeticholic acid 61-95 ATP binding cassette subfamily B member 4 Rattus norvegicus 191-195 18029909-4 2007 METHODS AND RESULTS: The FXR target gene, small heterodimer partner (SHP), was induced in vascular smooth muscle cells after treatment with synthetic FXR ligands, GW4064, or 6alpha-ethyl-chenodeoxycholic acid. obeticholic acid 174-208 nuclear receptor subfamily 1 group H member 4 Homo sapiens 25-28 18029909-4 2007 METHODS AND RESULTS: The FXR target gene, small heterodimer partner (SHP), was induced in vascular smooth muscle cells after treatment with synthetic FXR ligands, GW4064, or 6alpha-ethyl-chenodeoxycholic acid. obeticholic acid 174-208 nuclear receptor subfamily 0 group B member 2 Homo sapiens 42-67 18029909-4 2007 METHODS AND RESULTS: The FXR target gene, small heterodimer partner (SHP), was induced in vascular smooth muscle cells after treatment with synthetic FXR ligands, GW4064, or 6alpha-ethyl-chenodeoxycholic acid. obeticholic acid 174-208 nuclear receptor subfamily 0 group B member 2 Homo sapiens 69-72 15980055-4 2005 Exposure of cells to natural and synthetic ligands of FXR, including 6-ethyl chenodeoxycholic acid (6-ECDCA), a synthetic derivative of chenodeoxycholic acid, reversed this effect and increased PPARgamma mRNA by approximately 40-fold. obeticholic acid 69-98 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 54-57 15980055-4 2005 Exposure of cells to natural and synthetic ligands of FXR, including 6-ethyl chenodeoxycholic acid (6-ECDCA), a synthetic derivative of chenodeoxycholic acid, reversed this effect and increased PPARgamma mRNA by approximately 40-fold. obeticholic acid 69-98 peroxisome proliferator-activated receptor gamma Rattus norvegicus 194-203 15980055-4 2005 Exposure of cells to natural and synthetic ligands of FXR, including 6-ethyl chenodeoxycholic acid (6-ECDCA), a synthetic derivative of chenodeoxycholic acid, reversed this effect and increased PPARgamma mRNA by approximately 40-fold. obeticholic acid 100-107 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 54-57 15980055-4 2005 Exposure of cells to natural and synthetic ligands of FXR, including 6-ethyl chenodeoxycholic acid (6-ECDCA), a synthetic derivative of chenodeoxycholic acid, reversed this effect and increased PPARgamma mRNA by approximately 40-fold. obeticholic acid 100-107 peroxisome proliferator-activated receptor gamma Rattus norvegicus 194-203 15980055-6 2005 Administration of 6-ECDCA in rats rendered cirrhotic by porcine serum and carbon tetrachloride administration or bile duct ligation reverted down-regulation of PPARgamma mRNA expression in HSCs. obeticholic acid 18-25 peroxisome proliferator-activated receptor gamma Rattus norvegicus 160-169 16178789-9 2005 In vivo administration of 6-ECDCA protects against cholestasis induced by estrogen and LCA in rats providing evidence that development of potent FXR agonists might represent a new approach for the treatment of cholestastic disorders. obeticholic acid 26-33 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 145-148 15521018-4 2004 RESULTS: Twelve-week administration of 1-10 mg/kg 6-ethyl chenodeoxycholic acid (6-ECDCA), a synthetic FXR ligand, to porcine serum-treated rats prevented liver fibrosis development and reduced liver expression of alpha1(I) collagen, TGF-beta1 and alpha-SMA mRNA by approximately 90%. obeticholic acid 50-79 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 103-106 15860571-2 2005 In the present study, we investigated whether 6-ethyl chenodeoxycholic acid (6-ECDCA or INT-747), a semisynthetic derivative of chenodeoxycholic acid (CDCA), modulates tissue metalloproteinase inhibitor (TIMP)-1 and matrix metalloprotease (MMP)-2 expression/activity in HSCs and in the liver of rats rendered cirrhotic by 4-week administration of CCl(4). obeticholic acid 46-75 TIMP metallopeptidase inhibitor 1 Rattus norvegicus 175-211 15860571-2 2005 In the present study, we investigated whether 6-ethyl chenodeoxycholic acid (6-ECDCA or INT-747), a semisynthetic derivative of chenodeoxycholic acid (CDCA), modulates tissue metalloproteinase inhibitor (TIMP)-1 and matrix metalloprotease (MMP)-2 expression/activity in HSCs and in the liver of rats rendered cirrhotic by 4-week administration of CCl(4). obeticholic acid 46-75 matrix metallopeptidase 2 Rattus norvegicus 216-246 15860571-2 2005 In the present study, we investigated whether 6-ethyl chenodeoxycholic acid (6-ECDCA or INT-747), a semisynthetic derivative of chenodeoxycholic acid (CDCA), modulates tissue metalloproteinase inhibitor (TIMP)-1 and matrix metalloprotease (MMP)-2 expression/activity in HSCs and in the liver of rats rendered cirrhotic by 4-week administration of CCl(4). obeticholic acid 77-84 TIMP metallopeptidase inhibitor 1 Rattus norvegicus 175-211 15860571-6 2005 Administration of 3 mg/kg 6-ECDCA, but not 15 mg/kg ursodeoxycholic acid, resulted in early (3-5-day) induction of SHP and prevention of early up-regulation of TIMP-1 mRNA induced by CCl(4). obeticholic acid 26-33 nuclear receptor subfamily 0, group B, member 2 Rattus norvegicus 115-118 15860571-6 2005 Administration of 3 mg/kg 6-ECDCA, but not 15 mg/kg ursodeoxycholic acid, resulted in early (3-5-day) induction of SHP and prevention of early up-regulation of TIMP-1 mRNA induced by CCl(4). obeticholic acid 26-33 TIMP metallopeptidase inhibitor 1 Rattus norvegicus 160-166 15911693-4 2005 6-Ethyl CDCA (6-ECDCA) is a synthetic BA that binds FXR and induces gene transcription by recruiting coactivators, such as steroid receptor coactivator-1, with histone acetyltransferase activity. obeticholic acid 0-12 nuclear receptor subfamily 1 group H member 4 Homo sapiens 52-55 15911693-4 2005 6-Ethyl CDCA (6-ECDCA) is a synthetic BA that binds FXR and induces gene transcription by recruiting coactivators, such as steroid receptor coactivator-1, with histone acetyltransferase activity. obeticholic acid 14-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 52-55 15911693-6 2005 In the present study, we demonstrated that 6-ECDCA activates FXR to interacts with Protein Arginine Methyl-Transferase type I (PRMT1), which induces up-regulation of bile salt export pump (BSEP) and the small heterodimer partner (SHP) mRNA expression and causes a down-regulation of P450 cholesterol 7alpha-hydroxylase and Na(+) taurocholate cotransport peptide genes. obeticholic acid 43-50 nuclear receptor subfamily 1 group H member 4 Homo sapiens 61-64 15911693-6 2005 In the present study, we demonstrated that 6-ECDCA activates FXR to interacts with Protein Arginine Methyl-Transferase type I (PRMT1), which induces up-regulation of bile salt export pump (BSEP) and the small heterodimer partner (SHP) mRNA expression and causes a down-regulation of P450 cholesterol 7alpha-hydroxylase and Na(+) taurocholate cotransport peptide genes. obeticholic acid 43-50 protein arginine methyltransferase 1 Homo sapiens 127-132 15911693-6 2005 In the present study, we demonstrated that 6-ECDCA activates FXR to interacts with Protein Arginine Methyl-Transferase type I (PRMT1), which induces up-regulation of bile salt export pump (BSEP) and the small heterodimer partner (SHP) mRNA expression and causes a down-regulation of P450 cholesterol 7alpha-hydroxylase and Na(+) taurocholate cotransport peptide genes. obeticholic acid 43-50 ATP binding cassette subfamily B member 11 Homo sapiens 166-187 15911693-6 2005 In the present study, we demonstrated that 6-ECDCA activates FXR to interacts with Protein Arginine Methyl-Transferase type I (PRMT1), which induces up-regulation of bile salt export pump (BSEP) and the small heterodimer partner (SHP) mRNA expression and causes a down-regulation of P450 cholesterol 7alpha-hydroxylase and Na(+) taurocholate cotransport peptide genes. obeticholic acid 43-50 ATP binding cassette subfamily B member 11 Homo sapiens 189-193 15911693-6 2005 In the present study, we demonstrated that 6-ECDCA activates FXR to interacts with Protein Arginine Methyl-Transferase type I (PRMT1), which induces up-regulation of bile salt export pump (BSEP) and the small heterodimer partner (SHP) mRNA expression and causes a down-regulation of P450 cholesterol 7alpha-hydroxylase and Na(+) taurocholate cotransport peptide genes. obeticholic acid 43-50 nuclear receptor subfamily 0 group B member 2 Homo sapiens 203-228 15911693-6 2005 In the present study, we demonstrated that 6-ECDCA activates FXR to interacts with Protein Arginine Methyl-Transferase type I (PRMT1), which induces up-regulation of bile salt export pump (BSEP) and the small heterodimer partner (SHP) mRNA expression and causes a down-regulation of P450 cholesterol 7alpha-hydroxylase and Na(+) taurocholate cotransport peptide genes. obeticholic acid 43-50 nuclear receptor subfamily 0 group B member 2 Homo sapiens 230-233 15911693-7 2005 Chromatin immunoprecipitation assay suggests that 6-ECDCA induces both the recruitment of PRMT1 and the H4 methylation to the promoter of BSEP and SHP genes. obeticholic acid 50-57 protein arginine methyltransferase 1 Homo sapiens 90-95 15911693-7 2005 Chromatin immunoprecipitation assay suggests that 6-ECDCA induces both the recruitment of PRMT1 and the H4 methylation to the promoter of BSEP and SHP genes. obeticholic acid 50-57 ATP binding cassette subfamily B member 11 Homo sapiens 138-142 15911693-7 2005 Chromatin immunoprecipitation assay suggests that 6-ECDCA induces both the recruitment of PRMT1 and the H4 methylation to the promoter of BSEP and SHP genes. obeticholic acid 50-57 nuclear receptor subfamily 0 group B member 2 Homo sapiens 147-150 15644430-3 2005 Here, we describe the effect of 6-ethyl chenodeoxycholic acid (6-ECDCA or INT-747), a semisynthetic bile acid derivative and potent FXR ligand, in a model of cholestasis induced by 5-day administration of 17alpha-ethynylestradiol (E(2)17alpha) to rats. obeticholic acid 32-61 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 132-135 15644430-3 2005 Here, we describe the effect of 6-ethyl chenodeoxycholic acid (6-ECDCA or INT-747), a semisynthetic bile acid derivative and potent FXR ligand, in a model of cholestasis induced by 5-day administration of 17alpha-ethynylestradiol (E(2)17alpha) to rats. obeticholic acid 63-70 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 132-135 15644430-7 2005 In vivo administration of 6-ECDCA increased liver expression of Shp, bsep, multidrug resistance-associated protein-2, and multidrug resistance protein-2, whereas it reduced cyp7a1 and cyp8b1 and ntcp mRNA. obeticholic acid 26-33 nuclear receptor subfamily 0, group B, member 2 Rattus norvegicus 64-67 15644430-7 2005 In vivo administration of 6-ECDCA increased liver expression of Shp, bsep, multidrug resistance-associated protein-2, and multidrug resistance protein-2, whereas it reduced cyp7a1 and cyp8b1 and ntcp mRNA. obeticholic acid 26-33 ATP binding cassette subfamily B member 11 Rattus norvegicus 69-73 15644430-7 2005 In vivo administration of 6-ECDCA increased liver expression of Shp, bsep, multidrug resistance-associated protein-2, and multidrug resistance protein-2, whereas it reduced cyp7a1 and cyp8b1 and ntcp mRNA. obeticholic acid 26-33 ATP binding cassette subfamily C member 2 Rattus norvegicus 75-116 15644430-7 2005 In vivo administration of 6-ECDCA increased liver expression of Shp, bsep, multidrug resistance-associated protein-2, and multidrug resistance protein-2, whereas it reduced cyp7a1 and cyp8b1 and ntcp mRNA. obeticholic acid 26-33 ATP binding cassette subfamily B member 4 Rattus norvegicus 122-152 15644430-7 2005 In vivo administration of 6-ECDCA increased liver expression of Shp, bsep, multidrug resistance-associated protein-2, and multidrug resistance protein-2, whereas it reduced cyp7a1 and cyp8b1 and ntcp mRNA. obeticholic acid 26-33 cytochrome P450 family 7 subfamily A member 1 Rattus norvegicus 173-179 15644430-7 2005 In vivo administration of 6-ECDCA increased liver expression of Shp, bsep, multidrug resistance-associated protein-2, and multidrug resistance protein-2, whereas it reduced cyp7a1 and cyp8b1 and ntcp mRNA. obeticholic acid 26-33 cytochrome P450 family 8 subfamily B member 1 Rattus norvegicus 184-190 15644430-7 2005 In vivo administration of 6-ECDCA increased liver expression of Shp, bsep, multidrug resistance-associated protein-2, and multidrug resistance protein-2, whereas it reduced cyp7a1 and cyp8b1 and ntcp mRNA. obeticholic acid 26-33 solute carrier family 10 member 1 Rattus norvegicus 195-199 15644430-9 2005 In conclusion, by demonstrating that 6-ECDCA protects against E(2)17alpha cholestasis, our data support the notion that development of potent FXR ligands might represent a new approach for the treatment of cholestatic disorders. obeticholic acid 37-44 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 142-145 15521018-4 2004 RESULTS: Twelve-week administration of 1-10 mg/kg 6-ethyl chenodeoxycholic acid (6-ECDCA), a synthetic FXR ligand, to porcine serum-treated rats prevented liver fibrosis development and reduced liver expression of alpha1(I) collagen, TGF-beta1 and alpha-SMA mRNA by approximately 90%. obeticholic acid 50-79 transforming growth factor, beta 1 Rattus norvegicus 234-243 15521018-4 2004 RESULTS: Twelve-week administration of 1-10 mg/kg 6-ethyl chenodeoxycholic acid (6-ECDCA), a synthetic FXR ligand, to porcine serum-treated rats prevented liver fibrosis development and reduced liver expression of alpha1(I) collagen, TGF-beta1 and alpha-SMA mRNA by approximately 90%. obeticholic acid 81-88 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 103-106 15521018-4 2004 RESULTS: Twelve-week administration of 1-10 mg/kg 6-ethyl chenodeoxycholic acid (6-ECDCA), a synthetic FXR ligand, to porcine serum-treated rats prevented liver fibrosis development and reduced liver expression of alpha1(I) collagen, TGF-beta1 and alpha-SMA mRNA by approximately 90%. obeticholic acid 81-88 transforming growth factor, beta 1 Rattus norvegicus 234-243 15521018-5 2004 Therapeutic administration of 6-ECDCA, 3 mg/kg, to BDL rats reduced liver fibrosis and alpha1(I) collagen, transforming growth factor (TGF)-beta1, alpha-SMA, and tissue metalloproteinase inhibitor (TIMP)-1 and 2 messenger RNA (mRNA) by 70%-80%. obeticholic acid 30-37 TIMP metallopeptidase inhibitor 1 Rattus norvegicus 169-211 12749886-0 2003 Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR). obeticholic acid 16-22 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 68-78 15317466-4 2004 We have previously shown that 6alpha-ethyl-CDCA (6ECDCA) is a potent and selective FXR agonist. obeticholic acid 49-55 nuclear receptor subfamily 1 group H member 4 Homo sapiens 83-86 12749886-0 2003 Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR). obeticholic acid 16-22 nuclear receptor subfamily 1 group H member 4 Homo sapiens 80-83 12166927-0 2002 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. obeticholic acid 0-34 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 69-72 12166927-0 2002 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. obeticholic acid 36-43 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 69-72 12166927-2 2002 Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis. obeticholic acid 12-46 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 101-104 12166927-2 2002 Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis. obeticholic acid 48-55 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 101-104 33761646-8 2021 The ranking results among the hepatic biochemical indicators showed that obeticholic acid (94.9%) and elafibranor (86.3%) have a relative advantage in reducing alanine aminotransferase (ALT) levels, and obeticholic acid also had an advantage (95.4%) in reducing aspartate aminotransferase (AST) levels. obeticholic acid 73-89 glutamic--pyruvic transaminase Homo sapiens 160-184 33761646-8 2021 The ranking results among the hepatic biochemical indicators showed that obeticholic acid (94.9%) and elafibranor (86.3%) have a relative advantage in reducing alanine aminotransferase (ALT) levels, and obeticholic acid also had an advantage (95.4%) in reducing aspartate aminotransferase (AST) levels. obeticholic acid 73-89 solute carrier family 17 member 5 Homo sapiens 262-288 33761646-8 2021 The ranking results among the hepatic biochemical indicators showed that obeticholic acid (94.9%) and elafibranor (86.3%) have a relative advantage in reducing alanine aminotransferase (ALT) levels, and obeticholic acid also had an advantage (95.4%) in reducing aspartate aminotransferase (AST) levels. obeticholic acid 73-89 solute carrier family 17 member 5 Homo sapiens 290-293 34832899-8 2021 We also detected isoniazid-induced inhibition of caspase 3 activity in zebrafish that were treated with the hepatoprotectants ursodeoxycholic acid and obeticholic acid. obeticholic acid 151-167 caspase 3, apoptosis-related cysteine peptidase a Danio rerio 49-58 34957043-4 2021 This study explores the interactions of the BA, obeticholic acid (OCA), with DAT and characterizes the regulation of DAT activity via both electrophysiology and molecular modeling. obeticholic acid 48-64 solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 Mus musculus 77-80 34957043-4 2021 This study explores the interactions of the BA, obeticholic acid (OCA), with DAT and characterizes the regulation of DAT activity via both electrophysiology and molecular modeling. obeticholic acid 66-69 solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 Mus musculus 77-80 34774795-7 2021 We also show treatment of mice after CBDL with the potent nuclear receptor FXR agonist obeticholic acid (OCA) significantly increased Abcb11 mRNA and protein and decreased miR-199a-5p expression. obeticholic acid 87-103 nuclear receptor subfamily 1, group H, member 4 Mus musculus 75-78 34774795-7 2021 We also show treatment of mice after CBDL with the potent nuclear receptor FXR agonist obeticholic acid (OCA) significantly increased Abcb11 mRNA and protein and decreased miR-199a-5p expression. obeticholic acid 87-103 ATP-binding cassette, sub-family B (MDR/TAP), member 11 Mus musculus 134-140 34774795-12 2021 In conclusion, we demonstrate that miR-199a-5p is involved in regulating ABCB11/Abcb11 expression, is aberrantly upregulated in obstructive cholestasis, and is downregulated by the FXR agonist obeticholic acid. obeticholic acid 193-209 ATP-binding cassette, sub-family B (MDR/TAP), member 11 Mus musculus 73-79 34774795-12 2021 In conclusion, we demonstrate that miR-199a-5p is involved in regulating ABCB11/Abcb11 expression, is aberrantly upregulated in obstructive cholestasis, and is downregulated by the FXR agonist obeticholic acid. obeticholic acid 193-209 ATP-binding cassette, sub-family B (MDR/TAP), member 11 Mus musculus 80-86 34774795-12 2021 In conclusion, we demonstrate that miR-199a-5p is involved in regulating ABCB11/Abcb11 expression, is aberrantly upregulated in obstructive cholestasis, and is downregulated by the FXR agonist obeticholic acid. obeticholic acid 193-209 nuclear receptor subfamily 1, group H, member 4 Mus musculus 181-184 34410012-9 2021 Administration of the FXR agonist obeticholic acid reduced liver injury and tumor incidence in Abcb11-/- mice. obeticholic acid 34-50 nuclear receptor subfamily 1, group H, member 4 Mus musculus 22-25 34410012-9 2021 Administration of the FXR agonist obeticholic acid reduced liver injury and tumor incidence in Abcb11-/- mice. obeticholic acid 34-50 ATP-binding cassette, sub-family B (MDR/TAP), member 11 Mus musculus 95-101 34793868-10 2022 The greatest improvements were observed in patients with >=1-stage fibrosis improvement; however, improvements in ALT, AST, FIB-4, and FibroTest were also observed in OCA-treated patients whose histologic fibrosis remained stable. obeticholic acid 167-170 solute carrier family 17 member 5 Homo sapiens 119-122 34345273-6 2021 OCA treatment enhanced brown adipocyte cell differentiation and upregulated the expression of the BAT-specific gene Ucp1) in C3H10T1/2 cells in vitro. obeticholic acid 0-3 uncoupling protein 1 (mitochondrial, proton carrier) Mus musculus 116-120 34510838-10 2021 Conclusion: Although OCA did not appear to reduce BT by pathogenic bacteria, the reduction in intestinal content of Enterococcus, which has been associated with hepatocyte death, in OCA-treated animals is consistent with our observed improvements in AST and in liver function, as evidenced by higher serum albumin. obeticholic acid 182-185 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 250-253 34510838-10 2021 Conclusion: Although OCA did not appear to reduce BT by pathogenic bacteria, the reduction in intestinal content of Enterococcus, which has been associated with hepatocyte death, in OCA-treated animals is consistent with our observed improvements in AST and in liver function, as evidenced by higher serum albumin. obeticholic acid 182-185 albumin Rattus norvegicus 300-313 34256254-2 2021 Obeticholic acid (OCA), a FXR agonist which was synthesized from chenodeoxycholic acid, showed desirable curative effects in clinical trials. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 26-29 34483922-4 2021 7-ELCA significantly suppressed the effect of the FXR agonist obeticholic acid in BSEP and SHP regulation in human hepatocytes. obeticholic acid 62-78 nuclear receptor subfamily 1 group H member 4 Homo sapiens 50-53 34483922-4 2021 7-ELCA significantly suppressed the effect of the FXR agonist obeticholic acid in BSEP and SHP regulation in human hepatocytes. obeticholic acid 62-78 ATP binding cassette subfamily B member 11 Homo sapiens 82-86 34256254-2 2021 Obeticholic acid (OCA), a FXR agonist which was synthesized from chenodeoxycholic acid, showed desirable curative effects in clinical trials. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 26-29 35348137-10 2022 We then employ the MCA and the SVM training algorithm to prospectively identify the skin-sensitizing likelihood and mechanism-of-action for obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist which has undergone clinical trials for non-alcoholic steatohepatitis (NASH) with well-documented cutaneous side effects. obeticholic acid 140-156 nuclear receptor subfamily 1 group H member 4 Homo sapiens 166-186 35470044-2 2022 Obeticholic acid (OCA), a steroidal BA-like FXR agonist, has been shown to improve liver function in patients with primary biliary cholangitis and is approved as second-line treatment for patients with an inadequate response or intolerance to UDCA. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 44-47 35470044-11 2022 In conclusion, 4 weeks of OCA treatment oppositely modulates the hydrophobicity of the BA pool in WT and Cyp2c70-/- mice, but does not improve or worsen the characteristic sex-dependent liver pathology in Cyp2c70-/- mice. obeticholic acid 26-29 cytochrome P450, family 2, subfamily c, polypeptide 70 Mus musculus 105-112 35439472-0 2022 Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-beta1 axis. obeticholic acid 0-16 toll-like receptor 4 Mus musculus 130-134 35439472-0 2022 Obeticholic acid orchestrates the crosstalk between ileal autophagy and tight junctions in non-alcoholic steatohepatitis: Role of TLR4/TGF-beta1 axis. obeticholic acid 0-16 transforming growth factor, beta 1 Mus musculus 135-144 35439472-4 2022 Accordingly, the present study aimed at investigating the impact of the FXR agonist, obeticholic acid (OCA), on modulating the aberrant autophagy and intestinal integrity in NASH, exploring the possible implication of the TLR4/TGF-beta1 axis. obeticholic acid 85-101 nuclear receptor subfamily 1, group H, member 4 Mus musculus 72-75 35267068-3 2022 To reveal the intrinsic mechanism of FXR agonist-induce hepatotoxicity, two typical FXR agonists with different structures (obeticholic acid (OCA) and Px-102) were investigated in the present study. obeticholic acid 124-140 nuclear receptor subfamily 1, group H, member 4 Mus musculus 84-87 35267068-5 2022 Gene ablation or inhibition of FXR or SHP ameliorated the cytotoxicities of OCA and Px-102, which indicated the adverse actions of FXR/SHP activation including down-regulation of phosphorylation of PI3K/AKT and functional hepatic genes. obeticholic acid 76-79 nuclear receptor subfamily 1, group H, member 4 Mus musculus 31-34 35267068-5 2022 Gene ablation or inhibition of FXR or SHP ameliorated the cytotoxicities of OCA and Px-102, which indicated the adverse actions of FXR/SHP activation including down-regulation of phosphorylation of PI3K/AKT and functional hepatic genes. obeticholic acid 76-79 nuclear receptor subfamily 0, group B, member 2 Mus musculus 38-41 35267068-5 2022 Gene ablation or inhibition of FXR or SHP ameliorated the cytotoxicities of OCA and Px-102, which indicated the adverse actions of FXR/SHP activation including down-regulation of phosphorylation of PI3K/AKT and functional hepatic genes. obeticholic acid 76-79 nuclear receptor subfamily 1, group H, member 4 Mus musculus 131-134 35267068-5 2022 Gene ablation or inhibition of FXR or SHP ameliorated the cytotoxicities of OCA and Px-102, which indicated the adverse actions of FXR/SHP activation including down-regulation of phosphorylation of PI3K/AKT and functional hepatic genes. obeticholic acid 76-79 nuclear receptor subfamily 0, group B, member 2 Mus musculus 135-138 35267068-5 2022 Gene ablation or inhibition of FXR or SHP ameliorated the cytotoxicities of OCA and Px-102, which indicated the adverse actions of FXR/SHP activation including down-regulation of phosphorylation of PI3K/AKT and functional hepatic genes. obeticholic acid 76-79 thymoma viral proto-oncogene 1 Mus musculus 203-206 34149876-2 2021 The farnesoid X nuclear receptor (FXR) agonist obeticholic acid (OCA) has shown promise as a drug for NASH, but can adversely affect plasma lipid profiles. obeticholic acid 47-63 nuclear receptor subfamily 1, group H, member 4 Mus musculus 4-32 34149876-2 2021 The farnesoid X nuclear receptor (FXR) agonist obeticholic acid (OCA) has shown promise as a drug for NASH, but can adversely affect plasma lipid profiles. obeticholic acid 47-63 nuclear receptor subfamily 1, group H, member 4 Mus musculus 34-37 34149876-2 2021 The farnesoid X nuclear receptor (FXR) agonist obeticholic acid (OCA) has shown promise as a drug for NASH, but can adversely affect plasma lipid profiles. obeticholic acid 65-68 nuclear receptor subfamily 1, group H, member 4 Mus musculus 4-32 34149876-2 2021 The farnesoid X nuclear receptor (FXR) agonist obeticholic acid (OCA) has shown promise as a drug for NASH, but can adversely affect plasma lipid profiles. obeticholic acid 65-68 nuclear receptor subfamily 1, group H, member 4 Mus musculus 34-37 34200685-9 2021 Further study revealed that the intervention of obeticholic acid (OCA) could partly reverse the damage of CCl4. obeticholic acid 48-64 chemokine (C-C motif) ligand 4 Mus musculus 106-110 34200685-9 2021 Further study revealed that the intervention of obeticholic acid (OCA) could partly reverse the damage of CCl4. obeticholic acid 66-69 chemokine (C-C motif) ligand 4 Mus musculus 106-110 35470044-2 2022 Obeticholic acid (OCA), a steroidal BA-like FXR agonist, has been shown to improve liver function in patients with primary biliary cholangitis and is approved as second-line treatment for patients with an inadequate response or intolerance to UDCA. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 44-47 35477090-6 2022 Subsequent studies demonstrated that activation of FXR by its agonist obeticholic acid (OCA) directly promoted ASS1 transcription and enhanced arginine synthesis, leading to the alleviation of TAA-mediated liver injury. obeticholic acid 70-86 nuclear receptor subfamily 1 group H member 4 Homo sapiens 51-54 35477090-6 2022 Subsequent studies demonstrated that activation of FXR by its agonist obeticholic acid (OCA) directly promoted ASS1 transcription and enhanced arginine synthesis, leading to the alleviation of TAA-mediated liver injury. obeticholic acid 70-86 argininosuccinate synthase 1 Homo sapiens 111-115 35477090-6 2022 Subsequent studies demonstrated that activation of FXR by its agonist obeticholic acid (OCA) directly promoted ASS1 transcription and enhanced arginine synthesis, leading to the alleviation of TAA-mediated liver injury. obeticholic acid 88-91 nuclear receptor subfamily 1 group H member 4 Homo sapiens 51-54 35477090-6 2022 Subsequent studies demonstrated that activation of FXR by its agonist obeticholic acid (OCA) directly promoted ASS1 transcription and enhanced arginine synthesis, leading to the alleviation of TAA-mediated liver injury. obeticholic acid 88-91 argininosuccinate synthase 1 Homo sapiens 111-115 35447541-1 2022 OBJECTIVE: Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, is believed to alleviate nonalcoholic fatty liver disease (NAFLD) by decreasing hepatic lipogenesis in an FXR-dependent manner. obeticholic acid 11-27 nuclear receptor subfamily 1, group H, member 4 Mus musculus 37-57 35447541-1 2022 OBJECTIVE: Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, is believed to alleviate nonalcoholic fatty liver disease (NAFLD) by decreasing hepatic lipogenesis in an FXR-dependent manner. obeticholic acid 11-27 nuclear receptor subfamily 1, group H, member 4 Mus musculus 59-62 35447541-1 2022 OBJECTIVE: Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, is believed to alleviate nonalcoholic fatty liver disease (NAFLD) by decreasing hepatic lipogenesis in an FXR-dependent manner. obeticholic acid 11-27 nuclear receptor subfamily 1, group H, member 4 Mus musculus 179-182 35348137-10 2022 We then employ the MCA and the SVM training algorithm to prospectively identify the skin-sensitizing likelihood and mechanism-of-action for obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist which has undergone clinical trials for non-alcoholic steatohepatitis (NASH) with well-documented cutaneous side effects. obeticholic acid 140-156 nuclear receptor subfamily 1 group H member 4 Homo sapiens 188-191 35348137-10 2022 We then employ the MCA and the SVM training algorithm to prospectively identify the skin-sensitizing likelihood and mechanism-of-action for obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist which has undergone clinical trials for non-alcoholic steatohepatitis (NASH) with well-documented cutaneous side effects. obeticholic acid 158-161 nuclear receptor subfamily 1 group H member 4 Homo sapiens 188-191 34998040-6 2022 HEC96719 exhibits excellent potency superior to GW4064 and obeticholic acid in in vitro and in vivo assays of FXR activation. obeticholic acid 59-75 nuclear receptor subfamily 1 group H member 4 Homo sapiens 110-113 35614939-8 2022 Conclusion: The high-dose OCA induced FXR-dependent hepatic injury via cholesterol accumulation and interleukin -1beta pathway in the NAFLD mice. obeticholic acid 26-29 nuclear receptor subfamily 1, group H, member 4 Mus musculus 38-41 35614939-8 2022 Conclusion: The high-dose OCA induced FXR-dependent hepatic injury via cholesterol accumulation and interleukin -1beta pathway in the NAFLD mice. obeticholic acid 26-29 interleukin 1 beta Mus musculus 100-118 35631351-1 2022 We have previously demonstrated that the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) protects the liver via downregulation of hepatic matrix metalloproteinases (MMPs) after ischemia/reperfusion (I/R), which can lead to multiorgan dysfunction. obeticholic acid 76-92 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 41-61 35631351-1 2022 We have previously demonstrated that the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) protects the liver via downregulation of hepatic matrix metalloproteinases (MMPs) after ischemia/reperfusion (I/R), which can lead to multiorgan dysfunction. obeticholic acid 76-92 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 63-66 35348180-7 2022 In the present research study, we applied the molecular docking method in conjunction with molecular dynamics (MD) simulations to find out potential agonists for FXR based on structural similarity with the drug that is currently used as FXR agonist, obeticholic acid. obeticholic acid 250-266 nuclear receptor subfamily 1 group H member 4 Homo sapiens 162-165 35348180-7 2022 In the present research study, we applied the molecular docking method in conjunction with molecular dynamics (MD) simulations to find out potential agonists for FXR based on structural similarity with the drug that is currently used as FXR agonist, obeticholic acid. obeticholic acid 250-266 nuclear receptor subfamily 1 group H member 4 Homo sapiens 237-240 35614939-1 2022 Objective: Obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, is a promising drug for nonalcoholic fatty liver disease (NAFLD); however, it can cause liver injury, especially at high doses. obeticholic acid 11-27 nuclear receptor subfamily 1, group H, member 4 Mus musculus 44-64 35614939-1 2022 Objective: Obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, is a promising drug for nonalcoholic fatty liver disease (NAFLD); however, it can cause liver injury, especially at high doses. obeticholic acid 11-27 nuclear receptor subfamily 1, group H, member 4 Mus musculus 66-69 35614939-1 2022 Objective: Obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, is a promising drug for nonalcoholic fatty liver disease (NAFLD); however, it can cause liver injury, especially at high doses. obeticholic acid 29-32 nuclear receptor subfamily 1, group H, member 4 Mus musculus 44-64 35614939-1 2022 Objective: Obeticholic acid (OCA), a potent farnesoid X receptor (FXR) agonist, is a promising drug for nonalcoholic fatty liver disease (NAFLD); however, it can cause liver injury, especially at high doses. obeticholic acid 29-32 nuclear receptor subfamily 1, group H, member 4 Mus musculus 66-69 35614939-3 2022 Methods: Wild-type (WT) mice and FXR-/- mice were administered with over-dose OCA (0.40%) and high-dose OCA (0.16%), in a high-fat diet. obeticholic acid 78-81 nuclear receptor subfamily 1, group H, member 4 Mus musculus 33-36 35614939-6 2022 High-dose OCA caused hepatic stellate cell activation and liver fibrosis in the presence of FXR. obeticholic acid 10-13 nuclear receptor subfamily 1, group H, member 4 Mus musculus 92-95 35614939-7 2022 Furthermore, high-dose OCA induced cholesterol accumulation in livers via the upregulation of genes involved in cholesterol acquisition and downregulation of genes regulating cholesterol degradation in liver, leading to the production of interleukin -1beta and an FXR-mediated inflammatory response. obeticholic acid 23-26 interleukin 1 beta Mus musculus 238-256 35614939-7 2022 Furthermore, high-dose OCA induced cholesterol accumulation in livers via the upregulation of genes involved in cholesterol acquisition and downregulation of genes regulating cholesterol degradation in liver, leading to the production of interleukin -1beta and an FXR-mediated inflammatory response. obeticholic acid 23-26 nuclear receptor subfamily 1, group H, member 4 Mus musculus 264-267 35217809-4 2022 Despite the large number of FXR modulators reported, only obeticholic acid (OCA) has been approved for primary biliary cholangitis (PBC) therapy as FXR modulator. obeticholic acid 58-74 nuclear receptor subfamily 1 group H member 4 Homo sapiens 148-151 35217809-4 2022 Despite the large number of FXR modulators reported, only obeticholic acid (OCA) has been approved for primary biliary cholangitis (PBC) therapy as FXR modulator. obeticholic acid 76-79 nuclear receptor subfamily 1 group H member 4 Homo sapiens 148-151 35631351-6 2022 MMP-9-dimer activity in the kidney cortex and medulla increased after hepatic I/R and a reduction was detected in OCA-treated I/R rats. obeticholic acid 114-117 matrix metallopeptidase 9 Rattus norvegicus 0-5 35631351-7 2022 Although not significantly, MMP-2 activity decreased in the cortex of OCA-treated I/R rats. obeticholic acid 70-73 matrix metallopeptidase 2 Rattus norvegicus 28-33 35204252-4 2022 Obeticholic acid as a potent FXR agonist has been approved to treat primary biliary cholangitis and clinical trials for its use in the treatment of other liver diseases are underway. obeticholic acid 0-16 nuclear receptor subfamily 1, group H, member 4 Mus musculus 29-32 33704005-3 2021 Quantitative real-time PCR (QPCR) and western blot indicated that the above changes were accompanied by inhibition of farnesoid X receptor (FXR) signaling.Liver injury from TWT could be alleviated by treatment of the FXR agonist obeticholic acid (OCA) via activation of the FXR to inhibit the c-Jun N-terminal kinase (JNK) pathway and improve bile acid metabolism disorder by activating bile salt export pump (BSEP) and organic solute-transporter-beta (OSTB). obeticholic acid 229-245 nuclear receptor subfamily 1, group H, member 4 Mus musculus 140-143 34862975-5 2022 In mice feed a HFD, the treatment with obeticholic acid, a clinical stage FXR agonist, failed to improve the liver histopathology while reduced Cyp7a1 and Cyp8b1 genes expression and bile acids synthesis and excretion. obeticholic acid 39-55 nuclear receptor subfamily 1, group H, member 4 Mus musculus 74-77 34862975-5 2022 In mice feed a HFD, the treatment with obeticholic acid, a clinical stage FXR agonist, failed to improve the liver histopathology while reduced Cyp7a1 and Cyp8b1 genes expression and bile acids synthesis and excretion. obeticholic acid 39-55 cytochrome P450, family 7, subfamily a, polypeptide 1 Mus musculus 144-150 34862975-5 2022 In mice feed a HFD, the treatment with obeticholic acid, a clinical stage FXR agonist, failed to improve the liver histopathology while reduced Cyp7a1 and Cyp8b1 genes expression and bile acids synthesis and excretion. obeticholic acid 39-55 cytochrome P450, family 8, subfamily b, polypeptide 1 Mus musculus 155-161 33704005-3 2021 Quantitative real-time PCR (QPCR) and western blot indicated that the above changes were accompanied by inhibition of farnesoid X receptor (FXR) signaling.Liver injury from TWT could be alleviated by treatment of the FXR agonist obeticholic acid (OCA) via activation of the FXR to inhibit the c-Jun N-terminal kinase (JNK) pathway and improve bile acid metabolism disorder by activating bile salt export pump (BSEP) and organic solute-transporter-beta (OSTB). obeticholic acid 229-245 nuclear receptor subfamily 1, group H, member 4 Mus musculus 217-220 33704005-3 2021 Quantitative real-time PCR (QPCR) and western blot indicated that the above changes were accompanied by inhibition of farnesoid X receptor (FXR) signaling.Liver injury from TWT could be alleviated by treatment of the FXR agonist obeticholic acid (OCA) via activation of the FXR to inhibit the c-Jun N-terminal kinase (JNK) pathway and improve bile acid metabolism disorder by activating bile salt export pump (BSEP) and organic solute-transporter-beta (OSTB). obeticholic acid 229-245 nuclear receptor subfamily 1, group H, member 4 Mus musculus 217-220 34045606-3 2021 Here we investigated the potential of therapeutic bile acids ursodeoxycholic acid (UDCA) and obeticholic acid (OCA, 6-alpha-ethyl-CDCA), a farnesoid-X-receptor (FXR) agonist, as preventive treatment options for neonatal hyperbilirubinemia using the hUGT1*1 humanized mice and Ugt1a-deficient Gunn rats. obeticholic acid 93-109 nuclear receptor subfamily 1, group H, member 4 Mus musculus 139-159 33984334-0 2021 A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage. obeticholic acid 19-35 NLR family, pyrin domain containing 3 Mus musculus 68-73 33517537-9 2021 Furthermore, treatment with a TGF-beta inhibitor and a semi-synthetic bile acid analogue (obeticholic acid, phase 3 trial of NASH therapy) ameliorated the histological appearance of established iBHs. obeticholic acid 90-106 transforming growth factor alpha Mus musculus 30-38 33568795-3 2021 Hepatic FXR activation by obeticholic acid is currently used to treat primary biliary cholangitis. obeticholic acid 26-42 nuclear receptor subfamily 1, group H, member 4 Mus musculus 8-11 33995909-4 2021 With the approval of obeticholic acid (OCA) as the first small molecule to target FXR, many other small molecules are being evaluated in clinical trials. obeticholic acid 21-37 nuclear receptor subfamily 1 group H member 4 Homo sapiens 82-85 33995909-4 2021 With the approval of obeticholic acid (OCA) as the first small molecule to target FXR, many other small molecules are being evaluated in clinical trials. obeticholic acid 39-42 nuclear receptor subfamily 1 group H member 4 Homo sapiens 82-85 33916928-0 2021 Obeticholic Acid Derivative, T-2054 Suppresses Osteoarthritis via Inhibiting NF-kappaB-Signaling Pathway. obeticholic acid 0-16 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 77-86 33675775-4 2021 Herein, we investigated the effect of obeticholic acid (OCA), as an FXR agonist, on NASH-associated HCC (NASH-HCC) animal model induced by diethylnitrosamine and high fat choline-deficient diet, exploring the potential impact on the suppressor of cytokine signaling 3 (SOCS3)/Janus kinase 2 (Jak2)/signal transducer and activator of transcription 3 (STAT3) pathway. obeticholic acid 38-54 nuclear receptor subfamily 1 group H member 4 Homo sapiens 68-71 33784797-1 2021 Farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has emerged as a potential therapy for nonalcoholic fatty liver disease (NAFLD). obeticholic acid 35-51 nuclear receptor subfamily 1, group H, member 4 Mus musculus 0-20 33784797-1 2021 Farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has emerged as a potential therapy for nonalcoholic fatty liver disease (NAFLD). obeticholic acid 35-51 nuclear receptor subfamily 1, group H, member 4 Mus musculus 22-25 33784797-1 2021 Farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has emerged as a potential therapy for nonalcoholic fatty liver disease (NAFLD). obeticholic acid 35-51 bone gamma carboxyglutamate protein Mus musculus 53-56 32811993-9 2021 Treatment of HFD-fed mice with an FXR agonist Obeticholic acid, resulted in decreased primary BA synthesis, fewer C. difficile bacteria and better CDI outcomes. obeticholic acid 46-62 nuclear receptor subfamily 1, group H, member 4 Mus musculus 34-37 33154041-0 2021 Regulation of intestinal UGT1A1 by the FXR agonist obeticholic acid (OCA) is controlled by CAR through intestinal maturation. obeticholic acid 51-67 UDP glucuronosyltransferase 1 family, polypeptide A1 Mus musculus 25-31 33578971-0 2021 Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid. obeticholic acid 83-99 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 71-74 33578971-1 2021 : In a previous study, obeticholic acid (OCA) increased liver growth before partial hepatectomy (PHx) in rats through the bile acid receptor farnesoid X-receptor (FXR). obeticholic acid 23-39 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 163-166 33578971-9 2021 OCA treatment induced ileal Fgf15 mRNA expression but did not enhance post-PHx hepatocyte proliferation through FXR/SHP signaling. obeticholic acid 0-3 fibroblast growth factor 19 Rattus norvegicus 28-33 32583961-7 2021 Obeticholic acid showed reduction of fibrosis in adults with NASH taking 25mg daily for 18 months (n=931, reduction in fibrosis in 25% vs. 12% placebo, p<0.01). obeticholic acid 0-16 SAM domain, SH3 domain and nuclear localization signals 1 Homo sapiens 61-65 33049605-2 2021 Although the steroidal obeticholic acid, a full FXR agonist, was recently approved, several side effects probably due to insufficient pharmacological selectivity impede its further clinical application. obeticholic acid 23-39 nuclear receptor subfamily 1, group H, member 4 Mus musculus 48-51 33328206-6 2021 In obese mice, activation of FXR by obeticholic acid treatment reduced miR-802 levels and improved insulin resistance and hepatosteatosis, but these beneficial effects were largely abolished by overexpression of miR-802. obeticholic acid 36-52 nuclear receptor subfamily 1, group H, member 4 Mus musculus 29-32 33328206-6 2021 In obese mice, activation of FXR by obeticholic acid treatment reduced miR-802 levels and improved insulin resistance and hepatosteatosis, but these beneficial effects were largely abolished by overexpression of miR-802. obeticholic acid 36-52 microRNA 802 Mus musculus 71-78 33328206-6 2021 In obese mice, activation of FXR by obeticholic acid treatment reduced miR-802 levels and improved insulin resistance and hepatosteatosis, but these beneficial effects were largely abolished by overexpression of miR-802. obeticholic acid 36-52 microRNA 802 Mus musculus 212-219 33154041-0 2021 Regulation of intestinal UGT1A1 by the FXR agonist obeticholic acid (OCA) is controlled by CAR through intestinal maturation. obeticholic acid 51-67 nuclear receptor subfamily 1, group H, member 4 Mus musculus 39-42 33154041-0 2021 Regulation of intestinal UGT1A1 by the FXR agonist obeticholic acid (OCA) is controlled by CAR through intestinal maturation. obeticholic acid 51-67 nuclear receptor subfamily 1, group I, member 3 Mus musculus 91-94 33154041-3 2021 Neonatal humanized UGT1 mice (hUGT1), which accumulate severe levels of total serum bilirubin (TSB), were treated by oral gavage with obeticholic acid (OCA), a potent FXR agonist. obeticholic acid 134-150 nuclear receptor subfamily 1, group H, member 4 Mus musculus 167-170 33154041-12 2021 Thus, new findings link an important role for CAR in intestinal UGT1A1 induction and its role in the intestinal maturation pathway Significance Statement Obeticholic acid (OCA) activates FXR target genes in both liver and intestinal tissues while inducing intestinal UGT1A1 which leads to the elimination of serum bilirubin in hUGT1 mice. obeticholic acid 154-170 nuclear receptor subfamily 1, group I, member 3 Mus musculus 46-49 33154041-12 2021 Thus, new findings link an important role for CAR in intestinal UGT1A1 induction and its role in the intestinal maturation pathway Significance Statement Obeticholic acid (OCA) activates FXR target genes in both liver and intestinal tissues while inducing intestinal UGT1A1 which leads to the elimination of serum bilirubin in hUGT1 mice. obeticholic acid 154-170 UDP glucuronosyltransferase 1 family, polypeptide A1 Mus musculus 64-70 33154041-12 2021 Thus, new findings link an important role for CAR in intestinal UGT1A1 induction and its role in the intestinal maturation pathway Significance Statement Obeticholic acid (OCA) activates FXR target genes in both liver and intestinal tissues while inducing intestinal UGT1A1 which leads to the elimination of serum bilirubin in hUGT1 mice. obeticholic acid 154-170 nuclear receptor subfamily 1, group H, member 4 Mus musculus 187-190 33154041-12 2021 Thus, new findings link an important role for CAR in intestinal UGT1A1 induction and its role in the intestinal maturation pathway Significance Statement Obeticholic acid (OCA) activates FXR target genes in both liver and intestinal tissues while inducing intestinal UGT1A1 which leads to the elimination of serum bilirubin in hUGT1 mice. obeticholic acid 154-170 UDP glucuronosyltransferase 1 family, polypeptide A1 Mus musculus 267-273 33154041-12 2021 Thus, new findings link an important role for CAR in intestinal UGT1A1 induction and its role in the intestinal maturation pathway Significance Statement Obeticholic acid (OCA) activates FXR target genes in both liver and intestinal tissues while inducing intestinal UGT1A1 which leads to the elimination of serum bilirubin in hUGT1 mice. obeticholic acid 154-170 UDP-glucose glycoprotein glucosyltransferase 1 Homo sapiens 327-332 33290278-1 2020 Activation of Farnesoid-X-Receptor (FXR) by obeticholic acid (OCA) reduces hepatic inflammation and fibrosis in patients with primary biliary cholangitis (PBC), a life-threatening cholestatic liver failure. obeticholic acid 44-60 nuclear receptor subfamily 1 group H member 4 Homo sapiens 14-34 32717289-1 2021 BACKGROUND & AIMS: Obeticholic acid (OCA) is an agonist of the nuclear bile acid receptor FXR, which regulates hepatic bile acid metabolism. obeticholic acid 19-35 nuclear receptor subfamily 1 group H member 4 Homo sapiens 90-93 33364858-3 2020 Obeticholic acid, a farnesoid X receptor (FXR) agonist is the only agent approved by the Food and Drug Administration for patients who do not respond to UDCA. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 20-40 33364858-3 2020 Obeticholic acid, a farnesoid X receptor (FXR) agonist is the only agent approved by the Food and Drug Administration for patients who do not respond to UDCA. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 42-45 33308474-6 2020 For patients who do not respond sufficiently, or patients with ursodeoxycholic acid intolerance, conditionally licensed add-on therapy is with the FXR (NR1H4) agonist, obeticholic acid. obeticholic acid 168-184 nuclear receptor subfamily 1 group H member 4 Homo sapiens 147-150 33308474-6 2020 For patients who do not respond sufficiently, or patients with ursodeoxycholic acid intolerance, conditionally licensed add-on therapy is with the FXR (NR1H4) agonist, obeticholic acid. obeticholic acid 168-184 nuclear receptor subfamily 1 group H member 4 Homo sapiens 152-157 33290278-1 2020 Activation of Farnesoid-X-Receptor (FXR) by obeticholic acid (OCA) reduces hepatic inflammation and fibrosis in patients with primary biliary cholangitis (PBC), a life-threatening cholestatic liver failure. obeticholic acid 44-60 nuclear receptor subfamily 1 group H member 4 Homo sapiens 36-39 33290278-1 2020 Activation of Farnesoid-X-Receptor (FXR) by obeticholic acid (OCA) reduces hepatic inflammation and fibrosis in patients with primary biliary cholangitis (PBC), a life-threatening cholestatic liver failure. obeticholic acid 62-65 nuclear receptor subfamily 1 group H member 4 Homo sapiens 14-34 33290278-1 2020 Activation of Farnesoid-X-Receptor (FXR) by obeticholic acid (OCA) reduces hepatic inflammation and fibrosis in patients with primary biliary cholangitis (PBC), a life-threatening cholestatic liver failure. obeticholic acid 62-65 nuclear receptor subfamily 1 group H member 4 Homo sapiens 36-39 33304784-3 2020 Taking advantage of the intrinsic property of LSECs in capturing circulating nanoparticles in the circulation, we proposed a strategy using nanoemulsion-loaded obeticholic acid (OCA), a clinically approved selective farnesoid X receptor (FXR) agonist, for precisely manipulating LSECs for triggering NKT cell-mediated liver cancer immunotherapy. obeticholic acid 160-176 nuclear receptor subfamily 1, group H, member 4 Mus musculus 216-236 33164339-2 2020 The FXR agonist obeticholic acid (OCA) has preliminarily displayed tumour suppressor potential. obeticholic acid 16-32 nuclear receptor subfamily 1 group H member 4 Homo sapiens 4-7 33164339-2 2020 The FXR agonist obeticholic acid (OCA) has preliminarily displayed tumour suppressor potential. obeticholic acid 34-37 nuclear receptor subfamily 1 group H member 4 Homo sapiens 4-7 33304784-3 2020 Taking advantage of the intrinsic property of LSECs in capturing circulating nanoparticles in the circulation, we proposed a strategy using nanoemulsion-loaded obeticholic acid (OCA), a clinically approved selective farnesoid X receptor (FXR) agonist, for precisely manipulating LSECs for triggering NKT cell-mediated liver cancer immunotherapy. obeticholic acid 160-176 nuclear receptor subfamily 1, group H, member 4 Mus musculus 238-241 33304784-3 2020 Taking advantage of the intrinsic property of LSECs in capturing circulating nanoparticles in the circulation, we proposed a strategy using nanoemulsion-loaded obeticholic acid (OCA), a clinically approved selective farnesoid X receptor (FXR) agonist, for precisely manipulating LSECs for triggering NKT cell-mediated liver cancer immunotherapy. obeticholic acid 178-181 nuclear receptor subfamily 1, group H, member 4 Mus musculus 216-236 33304784-3 2020 Taking advantage of the intrinsic property of LSECs in capturing circulating nanoparticles in the circulation, we proposed a strategy using nanoemulsion-loaded obeticholic acid (OCA), a clinically approved selective farnesoid X receptor (FXR) agonist, for precisely manipulating LSECs for triggering NKT cell-mediated liver cancer immunotherapy. obeticholic acid 178-181 nuclear receptor subfamily 1, group H, member 4 Mus musculus 238-241 32712104-8 2020 We used the FXR ligand obeticholic acid to induce FXR activity in organoids, cell lines and mice. obeticholic acid 23-39 nuclear receptor subfamily 1, group H, member 4 Mus musculus 12-15 32712104-8 2020 We used the FXR ligand obeticholic acid to induce FXR activity in organoids, cell lines and mice. obeticholic acid 23-39 nuclear receptor subfamily 1, group H, member 4 Mus musculus 50-53 32712104-12 2020 Incubation with obeticholic acid increased mitochondrial pyruvate transport and reduced insulin-induced lipogenesis in organoids that expressed FXRalpha2 but not FXRalpha1. obeticholic acid 16-32 insulin Homo sapiens 88-95 33059584-6 2020 Obeticholic acid (OCA, 30 mg/kg, QD) was administered in both MS-NASH and C57Bl/6 mice fed WDF and treated with CCl4 (0.08 mL/kg). obeticholic acid 0-16 chemokine (C-C motif) ligand 4 Mus musculus 112-116 33059584-11 2020 OCA treatment significantly lowered liver triglycerides, steatosis and fibrosis in both MS-NASH and C57Bl/6 mice fed WDF with CCl4 treatment. obeticholic acid 0-3 chemokine (C-C motif) ligand 4 Mus musculus 126-130 32841642-2 2020 Recently obeticholic acid, a farnesoid X receptor (FXR) agonist, was FDA-approved to treat cholestatic liver diseases, providing a new therapeutic strategy for cholestasis. obeticholic acid 9-25 nuclear receptor subfamily 1 group H member 4 Homo sapiens 29-49 32841642-2 2020 Recently obeticholic acid, a farnesoid X receptor (FXR) agonist, was FDA-approved to treat cholestatic liver diseases, providing a new therapeutic strategy for cholestasis. obeticholic acid 9-25 nuclear receptor subfamily 1 group H member 4 Homo sapiens 51-54 32725149-0 2020 Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2alpha-activated COX-TXA2 pathway. obeticholic acid 0-16 coproporphyrinogen oxidase Rattus norvegicus 131-139 33046820-0 2021 Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand. obeticholic acid 71-87 nuclear receptor subfamily 1 group H member 4 Homo sapiens 91-111 33319187-0 2021 Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. obeticholic acid 0-16 solute carrier family 17 member 5 Homo sapiens 52-55 32911524-1 2020 BACKGROUND: We have previously shown that obeticholic acid (OCA) upregulates the biliary excretion of asymmetric dimethylarginine (ADMA), an inhibitor of iNOS regulating the activity of matrix metalloproteinases (MMPs). obeticholic acid 42-58 nitric oxide synthase 2 Rattus norvegicus 154-158 32911524-1 2020 BACKGROUND: We have previously shown that obeticholic acid (OCA) upregulates the biliary excretion of asymmetric dimethylarginine (ADMA), an inhibitor of iNOS regulating the activity of matrix metalloproteinases (MMPs). obeticholic acid 42-58 matrix metallopeptidase 2 Rattus norvegicus 213-217 32911524-1 2020 BACKGROUND: We have previously shown that obeticholic acid (OCA) upregulates the biliary excretion of asymmetric dimethylarginine (ADMA), an inhibitor of iNOS regulating the activity of matrix metalloproteinases (MMPs). obeticholic acid 60-63 nitric oxide synthase 2 Rattus norvegicus 154-158 32911524-1 2020 BACKGROUND: We have previously shown that obeticholic acid (OCA) upregulates the biliary excretion of asymmetric dimethylarginine (ADMA), an inhibitor of iNOS regulating the activity of matrix metalloproteinases (MMPs). obeticholic acid 60-63 matrix metallopeptidase 2 Rattus norvegicus 213-217 32371093-0 2020 Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis. obeticholic acid 36-52 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 24-27 32371093-0 2020 Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis. obeticholic acid 36-52 MAF bZIP transcription factor G Rattus norvegicus 56-60 32371093-0 2020 Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis. obeticholic acid 36-52 NFE2 like bZIP transcription factor 2 Rattus norvegicus 65-69 32371093-2 2020 Obeticholic acid (OCA), the first in class of FXR agonist approved for clinical use, causes side effects including acute liver decompensation when administered to cirrhotic patients with primary biliary cholangitis at higher than recommended doses. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 46-49 32371093-2 2020 Obeticholic acid (OCA), the first in class of FXR agonist approved for clinical use, causes side effects including acute liver decompensation when administered to cirrhotic patients with primary biliary cholangitis at higher than recommended doses. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 46-49 32725149-1 2020 BACKGROUNDS/AIMS: The present study explores the potential of chronic treatment with the Foresaid X receptor (FXR) agonist obeticholic acid (OCA), which inhibits oxidative stress-related pathogenesis, in ascitic cirrhotic rats with hepatorenal syndrome (HRS) developed 6 weeks after bile duct ligation (BDL). obeticholic acid 123-139 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 89-108 32725149-1 2020 BACKGROUNDS/AIMS: The present study explores the potential of chronic treatment with the Foresaid X receptor (FXR) agonist obeticholic acid (OCA), which inhibits oxidative stress-related pathogenesis, in ascitic cirrhotic rats with hepatorenal syndrome (HRS) developed 6 weeks after bile duct ligation (BDL). obeticholic acid 123-139 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 110-113 32725149-1 2020 BACKGROUNDS/AIMS: The present study explores the potential of chronic treatment with the Foresaid X receptor (FXR) agonist obeticholic acid (OCA), which inhibits oxidative stress-related pathogenesis, in ascitic cirrhotic rats with hepatorenal syndrome (HRS) developed 6 weeks after bile duct ligation (BDL). obeticholic acid 141-144 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 89-108 32725149-1 2020 BACKGROUNDS/AIMS: The present study explores the potential of chronic treatment with the Foresaid X receptor (FXR) agonist obeticholic acid (OCA), which inhibits oxidative stress-related pathogenesis, in ascitic cirrhotic rats with hepatorenal syndrome (HRS) developed 6 weeks after bile duct ligation (BDL). obeticholic acid 141-144 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 110-113 32725149-6 2020 CONCLUSIONS: Through the inhibition of renal 8-iso-PGF2alpha production and the down-regulation of the COX-TXA2 pathway, our study suggests that chronic OCA treatment can ameliorate the HRS in ascitic cirrhotic rats. obeticholic acid 153-156 coproporphyrinogen oxidase Rattus norvegicus 103-111 32247663-6 2020 Obeticholic acid, a semi-synthetic bile acid used to treat PBC, under review for the treatment of NASH, and in development for the treatment of other metabolic disorders, induces OSTalpha/beta. obeticholic acid 0-16 solute carrier family 51 subunit alpha Homo sapiens 179-192 32505574-3 2020 Obeticholic acid (OCA) is the first-in-class BA-derived FXR agonist approved for the treatment of primary biliary cholangitis. obeticholic acid 0-16 nuclear receptor subfamily 1, group H, member 4 Mus musculus 56-59 32505574-3 2020 Obeticholic acid (OCA) is the first-in-class BA-derived FXR agonist approved for the treatment of primary biliary cholangitis. obeticholic acid 18-21 nuclear receptor subfamily 1, group H, member 4 Mus musculus 56-59 32982723-3 2020 Farnesoid X Receptor (FXR), a metabolic nuclear receptor, are found to be activated by primary BAs such as chenodeoxycholic acid (CDCA), cholic acid (CA) and synthetic agonists such as obeticholic acid (OCA). obeticholic acid 185-201 nuclear receptor subfamily 1 group H member 4 Homo sapiens 0-20 32982723-3 2020 Farnesoid X Receptor (FXR), a metabolic nuclear receptor, are found to be activated by primary BAs such as chenodeoxycholic acid (CDCA), cholic acid (CA) and synthetic agonists such as obeticholic acid (OCA). obeticholic acid 185-201 nuclear receptor subfamily 1 group H member 4 Homo sapiens 22-25 32982723-3 2020 Farnesoid X Receptor (FXR), a metabolic nuclear receptor, are found to be activated by primary BAs such as chenodeoxycholic acid (CDCA), cholic acid (CA) and synthetic agonists such as obeticholic acid (OCA). obeticholic acid 203-206 nuclear receptor subfamily 1 group H member 4 Homo sapiens 0-20 32982723-3 2020 Farnesoid X Receptor (FXR), a metabolic nuclear receptor, are found to be activated by primary BAs such as chenodeoxycholic acid (CDCA), cholic acid (CA) and synthetic agonists such as obeticholic acid (OCA). obeticholic acid 203-206 nuclear receptor subfamily 1 group H member 4 Homo sapiens 22-25 32532037-4 2020 This has led to the identification of the role of the farnesoid x receptor (FXR) in cholestatic liver diseases and, consequently, to the development of obeticholic acid (OCA), a steroid FXR agonist that has been recently approved for the treatment of PBC. obeticholic acid 152-168 nuclear receptor subfamily 1 group H member 4 Homo sapiens 54-74 32532037-4 2020 This has led to the identification of the role of the farnesoid x receptor (FXR) in cholestatic liver diseases and, consequently, to the development of obeticholic acid (OCA), a steroid FXR agonist that has been recently approved for the treatment of PBC. obeticholic acid 152-168 nuclear receptor subfamily 1 group H member 4 Homo sapiens 76-79 32532037-4 2020 This has led to the identification of the role of the farnesoid x receptor (FXR) in cholestatic liver diseases and, consequently, to the development of obeticholic acid (OCA), a steroid FXR agonist that has been recently approved for the treatment of PBC. obeticholic acid 152-168 nuclear receptor subfamily 1 group H member 4 Homo sapiens 186-189 32532037-4 2020 This has led to the identification of the role of the farnesoid x receptor (FXR) in cholestatic liver diseases and, consequently, to the development of obeticholic acid (OCA), a steroid FXR agonist that has been recently approved for the treatment of PBC. obeticholic acid 170-173 nuclear receptor subfamily 1 group H member 4 Homo sapiens 54-74 32532037-4 2020 This has led to the identification of the role of the farnesoid x receptor (FXR) in cholestatic liver diseases and, consequently, to the development of obeticholic acid (OCA), a steroid FXR agonist that has been recently approved for the treatment of PBC. obeticholic acid 170-173 nuclear receptor subfamily 1 group H member 4 Homo sapiens 76-79 32532037-4 2020 This has led to the identification of the role of the farnesoid x receptor (FXR) in cholestatic liver diseases and, consequently, to the development of obeticholic acid (OCA), a steroid FXR agonist that has been recently approved for the treatment of PBC. obeticholic acid 170-173 nuclear receptor subfamily 1 group H member 4 Homo sapiens 186-189 32098797-4 2020 Obeticholic acid (OCA) was used to activate FXR both in mice and in human hepatocellular carcinoma (Huh-7) cells. obeticholic acid 0-16 nuclear receptor subfamily 1, group H, member 4 Mus musculus 44-47 32237916-2 2020 They also consider the potential future strategies of combination therapies.Expert opinion: Farnesoid X receptor (FXR) agonist (obeticholic acid [OCA]) significantly ameliorated hepatic fibrosis in NASH stage 2/3 fibrosis in an interim analysis of phase 3 trial. obeticholic acid 128-144 nuclear receptor subfamily 1 group H member 4 Homo sapiens 92-112 32237916-2 2020 They also consider the potential future strategies of combination therapies.Expert opinion: Farnesoid X receptor (FXR) agonist (obeticholic acid [OCA]) significantly ameliorated hepatic fibrosis in NASH stage 2/3 fibrosis in an interim analysis of phase 3 trial. obeticholic acid 128-144 nuclear receptor subfamily 1 group H member 4 Homo sapiens 114-117 32237916-2 2020 They also consider the potential future strategies of combination therapies.Expert opinion: Farnesoid X receptor (FXR) agonist (obeticholic acid [OCA]) significantly ameliorated hepatic fibrosis in NASH stage 2/3 fibrosis in an interim analysis of phase 3 trial. obeticholic acid 146-149 nuclear receptor subfamily 1 group H member 4 Homo sapiens 92-112 32237916-2 2020 They also consider the potential future strategies of combination therapies.Expert opinion: Farnesoid X receptor (FXR) agonist (obeticholic acid [OCA]) significantly ameliorated hepatic fibrosis in NASH stage 2/3 fibrosis in an interim analysis of phase 3 trial. obeticholic acid 146-149 nuclear receptor subfamily 1 group H member 4 Homo sapiens 114-117 32436768-7 2020 FXR played a role in the hepatotoxicity of anti-tuberculosis drugs in the obeticholic acid treated and FXR-/- mice. obeticholic acid 74-90 nuclear receptor subfamily 1, group H, member 4 Mus musculus 0-3 32248018-4 2020 Here, this study observed the acute effect of lipopolysaccharide (LPS) on maternal bile acid of pregnant mice at gestational day 17 and the protective effect of obeticholic acid (OCA) pretreatment, a potent agonist of bile acid receptor farnesoid X receptor (FXR). obeticholic acid 161-177 nuclear receptor subfamily 1, group H, member 4 Mus musculus 259-262 32001325-5 2020 RESULTS: In cholestatic patients and individuals treated with the FXR ligand obeticholic acid (OCA) autophagy processing appeared to be impaired. obeticholic acid 77-93 nuclear receptor subfamily 1 group H member 4 Homo sapiens 66-69 32001325-5 2020 RESULTS: In cholestatic patients and individuals treated with the FXR ligand obeticholic acid (OCA) autophagy processing appeared to be impaired. obeticholic acid 95-98 nuclear receptor subfamily 1 group H member 4 Homo sapiens 66-69 32001325-6 2020 In vitro, chenodeoxycholic acid and OCA inhibited autophagy at the level of autophagosome-to-lysosome fusion in an FXR dependent manner. obeticholic acid 36-39 nuclear receptor subfamily 1 group H member 4 Homo sapiens 115-118 32098797-4 2020 Obeticholic acid (OCA) was used to activate FXR both in mice and in human hepatocellular carcinoma (Huh-7) cells. obeticholic acid 18-21 nuclear receptor subfamily 1, group H, member 4 Mus musculus 44-47 31940200-3 2020 While there are currently no approved therapies for NASH, the bile acid-derived FXR agonist obeticholic acid (OCA; 6-ethyl chenodeoxycholic acid) has shown promise in clinical studies. obeticholic acid 92-108 nuclear receptor subfamily 1 group H member 4 Homo sapiens 80-83 31940200-3 2020 While there are currently no approved therapies for NASH, the bile acid-derived FXR agonist obeticholic acid (OCA; 6-ethyl chenodeoxycholic acid) has shown promise in clinical studies. obeticholic acid 110-113 nuclear receptor subfamily 1 group H member 4 Homo sapiens 80-83 31940200-3 2020 While there are currently no approved therapies for NASH, the bile acid-derived FXR agonist obeticholic acid (OCA; 6-ethyl chenodeoxycholic acid) has shown promise in clinical studies. obeticholic acid 115-144 nuclear receptor subfamily 1 group H member 4 Homo sapiens 80-83 31680292-1 2020 Obeticholic acid (OCA) was approved for the treatment of primary biliary cholangitis (PBC) based on studies in patients with an alkaline phosphatase (ALP) level of at least 1.67 times the upper limit of normal (ULN) or elevated total bilirubin less than 2 times ULN.1 Postmarket reports of serious liver injury in patients receiving OCA prompted a boxed warning by the Food and Drug Administration (FDA). obeticholic acid 0-16 alkaline phosphatase, placental Homo sapiens 128-148 32282030-1 2020 INTRODUCTION: Obeticholic acid (OCA) is a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist of farnesoid X receptor (FXR), a key nuclear BA receptor, which induces expression of gut-derived hormones, in particular fibroblast growth factor 19. obeticholic acid 14-30 nuclear receptor subfamily 1 group H member 4 Homo sapiens 129-149 32282030-1 2020 INTRODUCTION: Obeticholic acid (OCA) is a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist of farnesoid X receptor (FXR), a key nuclear BA receptor, which induces expression of gut-derived hormones, in particular fibroblast growth factor 19. obeticholic acid 14-30 nuclear receptor subfamily 1 group H member 4 Homo sapiens 151-154 32282030-1 2020 INTRODUCTION: Obeticholic acid (OCA) is a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist of farnesoid X receptor (FXR), a key nuclear BA receptor, which induces expression of gut-derived hormones, in particular fibroblast growth factor 19. obeticholic acid 14-30 fibroblast growth factor 19 Homo sapiens 248-275 32118303-1 2020 The farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) axis has provided promising therapeutic targets for nonalcoholic steatohepatitis (NASH), with obeticholic acid (OCA), the first-in-class FXR agonist, showing fibrosis improvement in two human trials. obeticholic acid 161-177 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 14-24 32118303-1 2020 The farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) axis has provided promising therapeutic targets for nonalcoholic steatohepatitis (NASH), with obeticholic acid (OCA), the first-in-class FXR agonist, showing fibrosis improvement in two human trials. obeticholic acid 161-177 nuclear receptor subfamily 1 group H member 4 Homo sapiens 26-29 32118303-1 2020 The farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) axis has provided promising therapeutic targets for nonalcoholic steatohepatitis (NASH), with obeticholic acid (OCA), the first-in-class FXR agonist, showing fibrosis improvement in two human trials. obeticholic acid 161-177 fibroblast growth factor 19 Homo sapiens 31-58 32118303-1 2020 The farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) axis has provided promising therapeutic targets for nonalcoholic steatohepatitis (NASH), with obeticholic acid (OCA), the first-in-class FXR agonist, showing fibrosis improvement in two human trials. obeticholic acid 161-177 fibroblast growth factor 19 Homo sapiens 60-65 31680292-1 2020 Obeticholic acid (OCA) was approved for the treatment of primary biliary cholangitis (PBC) based on studies in patients with an alkaline phosphatase (ALP) level of at least 1.67 times the upper limit of normal (ULN) or elevated total bilirubin less than 2 times ULN.1 Postmarket reports of serious liver injury in patients receiving OCA prompted a boxed warning by the Food and Drug Administration (FDA). obeticholic acid 0-16 alkaline phosphatase, placental Homo sapiens 150-153 31680292-1 2020 Obeticholic acid (OCA) was approved for the treatment of primary biliary cholangitis (PBC) based on studies in patients with an alkaline phosphatase (ALP) level of at least 1.67 times the upper limit of normal (ULN) or elevated total bilirubin less than 2 times ULN.1 Postmarket reports of serious liver injury in patients receiving OCA prompted a boxed warning by the Food and Drug Administration (FDA). obeticholic acid 18-21 alkaline phosphatase, placental Homo sapiens 128-148 31680292-1 2020 Obeticholic acid (OCA) was approved for the treatment of primary biliary cholangitis (PBC) based on studies in patients with an alkaline phosphatase (ALP) level of at least 1.67 times the upper limit of normal (ULN) or elevated total bilirubin less than 2 times ULN.1 Postmarket reports of serious liver injury in patients receiving OCA prompted a boxed warning by the Food and Drug Administration (FDA). obeticholic acid 18-21 alkaline phosphatase, placental Homo sapiens 150-153 31883408-3 2020 METHODS: Mice were fed with a high fat diet (HFD) to induce obesity and NAFLD, and then treated with the FXR ligand obeticholic acid (OCA). obeticholic acid 116-132 nuclear receptor subfamily 1, group H, member 4 Mus musculus 105-108 31883408-3 2020 METHODS: Mice were fed with a high fat diet (HFD) to induce obesity and NAFLD, and then treated with the FXR ligand obeticholic acid (OCA). obeticholic acid 134-137 nuclear receptor subfamily 1, group H, member 4 Mus musculus 105-108 31883408-8 2020 FXR activation by OCA protected the liver against oxidative stress, apoptosis, and reduced 1-deoxysphingolipid levels, both in a HFD-induced mouse model of obesity and in 1-deoxysphinganine-treated mice. obeticholic acid 18-21 nuclear receptor subfamily 1, group H, member 4 Mus musculus 0-3 31883408-11 2020 Treatment with the Cyp4f pan-inhibitor HET0016 or FXR knockdown fully abolished the protective effect of OCA, indicating that OCA-mediated 1-deoxysphingolipid degradation is FXR- and Cyp4f-dependent. obeticholic acid 105-108 nuclear receptor subfamily 1, group H, member 4 Mus musculus 50-53 31883408-11 2020 Treatment with the Cyp4f pan-inhibitor HET0016 or FXR knockdown fully abolished the protective effect of OCA, indicating that OCA-mediated 1-deoxysphingolipid degradation is FXR- and Cyp4f-dependent. obeticholic acid 105-108 nuclear receptor subfamily 1, group H, member 4 Mus musculus 174-177 31883408-11 2020 Treatment with the Cyp4f pan-inhibitor HET0016 or FXR knockdown fully abolished the protective effect of OCA, indicating that OCA-mediated 1-deoxysphingolipid degradation is FXR- and Cyp4f-dependent. obeticholic acid 126-129 nuclear receptor subfamily 1, group H, member 4 Mus musculus 50-53 31883408-11 2020 Treatment with the Cyp4f pan-inhibitor HET0016 or FXR knockdown fully abolished the protective effect of OCA, indicating that OCA-mediated 1-deoxysphingolipid degradation is FXR- and Cyp4f-dependent. obeticholic acid 126-129 nuclear receptor subfamily 1, group H, member 4 Mus musculus 174-177 31919473-0 2020 Obeticholic acid for the treatment of NASH. obeticholic acid 0-16 SAM domain, SH3 domain and nuclear localization signals 1 Homo sapiens 38-42 32170842-1 2020 Obeticholic acid (OCA) activates the farnesoid X receptor (FXR) to lower circulating total cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) concentrations and to stimulate fecal cholesterol excretion in mice by increasing hepatic SR-B1 expression. obeticholic acid 0-16 nuclear receptor subfamily 1, group H, member 4 Mus musculus 37-57 32170842-1 2020 Obeticholic acid (OCA) activates the farnesoid X receptor (FXR) to lower circulating total cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) concentrations and to stimulate fecal cholesterol excretion in mice by increasing hepatic SR-B1 expression. obeticholic acid 0-16 nuclear receptor subfamily 1, group H, member 4 Mus musculus 59-62 32170842-1 2020 Obeticholic acid (OCA) activates the farnesoid X receptor (FXR) to lower circulating total cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) concentrations and to stimulate fecal cholesterol excretion in mice by increasing hepatic SR-B1 expression. obeticholic acid 0-16 scavenger receptor class B, member 1 Mus musculus 247-252 32170842-1 2020 Obeticholic acid (OCA) activates the farnesoid X receptor (FXR) to lower circulating total cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) concentrations and to stimulate fecal cholesterol excretion in mice by increasing hepatic SR-B1 expression. obeticholic acid 18-21 nuclear receptor subfamily 1, group H, member 4 Mus musculus 37-57 32170842-1 2020 Obeticholic acid (OCA) activates the farnesoid X receptor (FXR) to lower circulating total cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) concentrations and to stimulate fecal cholesterol excretion in mice by increasing hepatic SR-B1 expression. obeticholic acid 18-21 nuclear receptor subfamily 1, group H, member 4 Mus musculus 59-62 32170842-1 2020 Obeticholic acid (OCA) activates the farnesoid X receptor (FXR) to lower circulating total cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) concentrations and to stimulate fecal cholesterol excretion in mice by increasing hepatic SR-B1 expression. obeticholic acid 18-21 scavenger receptor class B, member 1 Mus musculus 247-252 32195457-16 2020 Consistent with this finding, an miR-22 inhibitor effectively reversed both alcohol- and diet-induced fatty liver; miR-22 inhibition is a promising therapeutic option which could be used in combination with obeticholic acid. obeticholic acid 207-223 microRNA 22 Mus musculus 33-39 32195457-16 2020 Consistent with this finding, an miR-22 inhibitor effectively reversed both alcohol- and diet-induced fatty liver; miR-22 inhibition is a promising therapeutic option which could be used in combination with obeticholic acid. obeticholic acid 207-223 microRNA 22 Mus musculus 115-121 32015483-8 2020 Co-treatment with OCA or INT-767 did not affect ACTA2 and COL1A1 expression, but significantly reduced FXR and induced SHP expression, as expected. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 103-106 32015483-8 2020 Co-treatment with OCA or INT-767 did not affect ACTA2 and COL1A1 expression, but significantly reduced FXR and induced SHP expression, as expected. obeticholic acid 18-21 nuclear receptor subfamily 0 group B member 2 Homo sapiens 119-122 32015483-9 2020 OCA induced a dose-dependent reduction of collagen and induced MMP2-9 activity. obeticholic acid 0-3 matrix metallopeptidase 2 Homo sapiens 63-69 32015483-13 2020 OCA exerted a more potent and long-lasting effect, mainly related to modulation of collagen turn-over and MMP2-9 activity. obeticholic acid 0-3 matrix metallopeptidase 2 Homo sapiens 106-112 31932588-4 2020 Activated HSCs show limited response to OCA and other FXR agonists due to enhanced FXR SUMOylation. obeticholic acid 40-43 nuclear receptor subfamily 1 group H member 4 Homo sapiens 83-86 31932588-7 2020 Therapeutic coadministration of OCA and SUMOylation inhibitors drastically impedes liver fibrosis induced by CCl4, bile duct ligation, and more importantly NASH. obeticholic acid 32-35 C-C motif chemokine ligand 4 Homo sapiens 109-113 31634532-1 2020 BACKGROUND: Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), increases total and low-density lipoprotein cholesterol (LDL-C) in patients with nonalcoholic steatohepatitis (NASH). obeticholic acid 48-64 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 22-32 31634532-1 2020 BACKGROUND: Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), increases total and low-density lipoprotein cholesterol (LDL-C) in patients with nonalcoholic steatohepatitis (NASH). obeticholic acid 48-64 nuclear receptor subfamily 1 group H member 4 Homo sapiens 34-37 31634532-1 2020 BACKGROUND: Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), increases total and low-density lipoprotein cholesterol (LDL-C) in patients with nonalcoholic steatohepatitis (NASH). obeticholic acid 66-69 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 22-32 31634532-1 2020 BACKGROUND: Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA), increases total and low-density lipoprotein cholesterol (LDL-C) in patients with nonalcoholic steatohepatitis (NASH). obeticholic acid 66-69 nuclear receptor subfamily 1 group H member 4 Homo sapiens 34-37 31634532-12 2020 Recently, obeticholic acid (OCA), a farnesoid X receptor agonist, improved liver disease but led to an increase in cholesterol, however, the impact of OCA on cholesterol is not well understood. obeticholic acid 10-26 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 46-56 31634532-12 2020 Recently, obeticholic acid (OCA), a farnesoid X receptor agonist, improved liver disease but led to an increase in cholesterol, however, the impact of OCA on cholesterol is not well understood. obeticholic acid 28-31 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 46-56 31832568-12 2019 The rs75508464 variant near CELA3B may have the most significant effect on NASH resolution in those receiving OCA. obeticholic acid 110-113 chymotrypsin like elastase 3B Homo sapiens 28-34 31813639-0 2019 Obeticholic acid: towards first approval for NASH. obeticholic acid 0-16 SAM domain, SH3 domain and nuclear localization signals 1 Homo sapiens 45-49 31812977-8 2019 Overexpression of FXR aggravated Ass-triggered neuronal apoptosis in differentiated SH-SY5Y cells, and this effect was further increased by treatment with the FXR agonist 6ECDCA. obeticholic acid 171-177 nuclear receptor subfamily 1 group H member 4 Homo sapiens 18-21 31812977-8 2019 Overexpression of FXR aggravated Ass-triggered neuronal apoptosis in differentiated SH-SY5Y cells, and this effect was further increased by treatment with the FXR agonist 6ECDCA. obeticholic acid 171-177 nuclear receptor subfamily 1 group H member 4 Homo sapiens 159-162 31419514-9 2019 The bile acid analogue and farnesoid X receptor agonist obeticholic acid drives beta-catenin activation in endothelial cells. obeticholic acid 56-72 catenin (cadherin associated protein), beta 1 Mus musculus 80-92 31472121-0 2019 CYP1A2 down-regulation by obeticholic acid: usefulness as a positive control for the in vitro evaluation of drug-drug interactions. obeticholic acid 26-42 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 0-6 31827696-12 2019 Moreover, OCA inhibited the upregulation of placental NADPH oxidase-4 and antioxidant genes during cholestasis. obeticholic acid 10-13 NADPH oxidase 4 Mus musculus 54-69 31827696-13 2019 OCA activated antioxidant Nrf2 signaling during cholestasis. obeticholic acid 0-3 nuclear factor, erythroid derived 2, like 2 Mus musculus 26-30 31325638-1 2019 Obeticholic acid (OCA) is a farnesoid-X-receptor (FXR) ligand, shown effective in reducing steatosis and fibrosis in NASH patients. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 28-48 31402538-2 2019 Although NASH has no approved treatments, obeticholic acid (OCA), a synthetic bile acid and farnesoid X receptor (FXR) agonist, was shown to improve histological features of NASH and fibrosis. obeticholic acid 42-58 nuclear receptor subfamily 1 group H member 4 Homo sapiens 92-112 31402538-2 2019 Although NASH has no approved treatments, obeticholic acid (OCA), a synthetic bile acid and farnesoid X receptor (FXR) agonist, was shown to improve histological features of NASH and fibrosis. obeticholic acid 42-58 nuclear receptor subfamily 1 group H member 4 Homo sapiens 114-117 31325638-1 2019 Obeticholic acid (OCA) is a farnesoid-X-receptor (FXR) ligand, shown effective in reducing steatosis and fibrosis in NASH patients. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 50-53 31325638-5 2019 In mice exposed to a diet rich in fat/cholesterol and fructose (HFD-F), treatment with OCA or UDCA effectively prevented body weight gain, insulin resistance, as demonstrated by OGTT, and AST plasma levels. obeticholic acid 87-90 transmembrane protease, serine 11d Mus musculus 188-191 31671330-0 2019 Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3. obeticholic acid 0-16 SMAD family member 3 Mus musculus 123-128 31671330-5 2019 OCA (5 mg/kg) or PBS is administered daily during CCl4-treatment. obeticholic acid 0-3 chemokine (C-C motif) ligand 4 Mus musculus 50-54 31671330-9 2019 Further experiments found that OCA pretreatment inhibited alpha-SMA expression and the activation of hepatic pSmad3 in 3 weeks group and 6 weeks group of CCl4-induced liver cirrhosis. obeticholic acid 31-34 actin alpha 2, smooth muscle, aorta Mus musculus 58-67 31671330-9 2019 Further experiments found that OCA pretreatment inhibited alpha-SMA expression and the activation of hepatic pSmad3 in 3 weeks group and 6 weeks group of CCl4-induced liver cirrhosis. obeticholic acid 31-34 chemokine (C-C motif) ligand 4 Mus musculus 154-158 31671330-10 2019 Moreover, OCA activated FXR nuclear translocation and increased the interaction between liver FXR and pSmad3. obeticholic acid 10-13 nuclear receptor subfamily 1, group H, member 4 Mus musculus 24-27 31671330-10 2019 Moreover, OCA activated FXR nuclear translocation and increased the interaction between liver FXR and pSmad3. obeticholic acid 10-13 nuclear receptor subfamily 1, group H, member 4 Mus musculus 94-97 31671330-12 2019 Our data suggest that CCl4-induced liver fibrosis is protected by OCA through interaction between farnesoid X receptor and Smad3. obeticholic acid 66-69 chemokine (C-C motif) ligand 4 Mus musculus 22-26 31671330-12 2019 Our data suggest that CCl4-induced liver fibrosis is protected by OCA through interaction between farnesoid X receptor and Smad3. obeticholic acid 66-69 SMAD family member 3 Mus musculus 123-128 31441502-4 2019 Potential second line treatments are also available when UDCA alone is not effective enough: the farnesoid X receptor (FXR) agonist obeticholic acid, conditionally approved by North American (FDA) and European (EMA) authorities as second line treatment in PBC, or the nonspecific peroxisomal proliferator-associated receptor (PPAR) agonist bezafibrate. obeticholic acid 132-148 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 107-117 31441502-4 2019 Potential second line treatments are also available when UDCA alone is not effective enough: the farnesoid X receptor (FXR) agonist obeticholic acid, conditionally approved by North American (FDA) and European (EMA) authorities as second line treatment in PBC, or the nonspecific peroxisomal proliferator-associated receptor (PPAR) agonist bezafibrate. obeticholic acid 132-148 nuclear receptor subfamily 1 group H member 4 Homo sapiens 119-122 31441502-4 2019 Potential second line treatments are also available when UDCA alone is not effective enough: the farnesoid X receptor (FXR) agonist obeticholic acid, conditionally approved by North American (FDA) and European (EMA) authorities as second line treatment in PBC, or the nonspecific peroxisomal proliferator-associated receptor (PPAR) agonist bezafibrate. obeticholic acid 132-148 peroxisome proliferator activated receptor alpha Homo sapiens 280-324 31441502-4 2019 Potential second line treatments are also available when UDCA alone is not effective enough: the farnesoid X receptor (FXR) agonist obeticholic acid, conditionally approved by North American (FDA) and European (EMA) authorities as second line treatment in PBC, or the nonspecific peroxisomal proliferator-associated receptor (PPAR) agonist bezafibrate. obeticholic acid 132-148 peroxisome proliferator activated receptor alpha Homo sapiens 326-330 31254596-1 2019 BACKGROUND & AIMS: The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has been developed for the treatment of liver diseases. obeticholic acid 70-86 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 45-55 31254596-1 2019 BACKGROUND & AIMS: The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has been developed for the treatment of liver diseases. obeticholic acid 70-86 nuclear receptor subfamily 1 group H member 4 Homo sapiens 57-60 31254596-1 2019 BACKGROUND & AIMS: The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has been developed for the treatment of liver diseases. obeticholic acid 88-91 xenotropic and polytropic retrovirus receptor 1 Homo sapiens 45-55 31254596-1 2019 BACKGROUND & AIMS: The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has been developed for the treatment of liver diseases. obeticholic acid 88-91 nuclear receptor subfamily 1 group H member 4 Homo sapiens 57-60 30963615-11 2019 Activin receptor-like kinase 5 (Alk5) inhibitor (Alk5i), nintedanib, and obeticholic acid therapy limited fibrogenesis in TGFbeta1/PDGFbetabeta-stimulated PCLSs, and Alk5i blunted progression of fibrosis in fibrotic PCLS. obeticholic acid 73-89 transforming growth factor beta 1 Homo sapiens 122-130 31177586-8 2019 Obeticholic acid inhibited hepatic TLR4 expression and increased hepatic matrix metalloproteinase-2 expression. obeticholic acid 0-16 toll-like receptor 4 Rattus norvegicus 35-39 31177586-8 2019 Obeticholic acid inhibited hepatic TLR4 expression and increased hepatic matrix metalloproteinase-2 expression. obeticholic acid 0-16 matrix metallopeptidase 2 Rattus norvegicus 73-99 31325638-1 2019 Obeticholic acid (OCA) is a farnesoid-X-receptor (FXR) ligand, shown effective in reducing steatosis and fibrosis in NASH patients. obeticholic acid 0-16 nuclear receptor subfamily 1 group H member 4 Homo sapiens 50-53 31325638-1 2019 Obeticholic acid (OCA) is a farnesoid-X-receptor (FXR) ligand, shown effective in reducing steatosis and fibrosis in NASH patients. obeticholic acid 18-21 nuclear receptor subfamily 1 group H member 4 Homo sapiens 28-48 31299240-0 2019 UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3. obeticholic acid 73-89 UDP glucuronosyltransferase family 1 member A complex locus Homo sapiens 0-3 31085240-0 2019 Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice. obeticholic acid 0-16 nuclear receptor subfamily 1, group H, member 4 Mus musculus 75-78 31085240-0 2019 Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice. obeticholic acid 0-16 nuclear factor, erythroid derived 2, like 2 Mus musculus 79-83 31085240-12 2019 In summary, FXR/Nrf2 signaling was involved in OCA-induced amelioration of metabolic disorder, oxidative stress, inflammation, fibrosis and myocardial dysfunction. obeticholic acid 47-50 nuclear receptor subfamily 1, group H, member 4 Mus musculus 12-15 31085240-12 2019 In summary, FXR/Nrf2 signaling was involved in OCA-induced amelioration of metabolic disorder, oxidative stress, inflammation, fibrosis and myocardial dysfunction. obeticholic acid 47-50 nuclear factor, erythroid derived 2, like 2 Mus musculus 16-20 31237448-4 2019 The FXR agonist, obeticholic acid (OCA), improves insulin sensitivity in patients with type 2 diabetes with nonalcoholic fatty liver disease. obeticholic acid 17-33 nuclear receptor subfamily 1 group H member 4 Homo sapiens 4-7 31237448-4 2019 The FXR agonist, obeticholic acid (OCA), improves insulin sensitivity in patients with type 2 diabetes with nonalcoholic fatty liver disease. obeticholic acid 17-33 insulin Homo sapiens 50-57 31388629-2 2019 The bile acid-derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients with nonalcoholic steatohepatitis (NASH). obeticholic acid 34-50 nuclear receptor subfamily 1 group H member 4 Homo sapiens 22-25 31388629-2 2019 The bile acid-derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients with nonalcoholic steatohepatitis (NASH). obeticholic acid 52-55 nuclear receptor subfamily 1 group H member 4 Homo sapiens 22-25 30928103-5 2019 Clinically, FXR and PPARalpha are the pharmacological targets of obeticholic acid and fenofibrate for the treatment of primary biliary cirrhosis, respectively. obeticholic acid 65-81 nuclear receptor subfamily 1 group H member 4 Homo sapiens 12-15 30928103-5 2019 Clinically, FXR and PPARalpha are the pharmacological targets of obeticholic acid and fenofibrate for the treatment of primary biliary cirrhosis, respectively. obeticholic acid 65-81 peroxisome proliferator activated receptor alpha Homo sapiens 20-29 30772394-3 2019 The present study aimed to investigate the effect of obeticholic acid (OCA), a novel synthetic FXR agonist, on D-galactosamine (GalN)/lipopolysaccharide (LPS)-evoked acute liver injury. obeticholic acid 53-69 nuclear receptor subfamily 1, group H, member 4 Mus musculus 95-98 30772394-3 2019 The present study aimed to investigate the effect of obeticholic acid (OCA), a novel synthetic FXR agonist, on D-galactosamine (GalN)/lipopolysaccharide (LPS)-evoked acute liver injury. obeticholic acid 71-74 nuclear receptor subfamily 1, group H, member 4 Mus musculus 95-98 30580099-11 2019 Activation of FXR by agonist obeticholic acid repressed the expression of ACSL1 protein and mRNA in the liver of FXR wild-type mice but not in FXR knockout mice. obeticholic acid 29-45 nuclear receptor subfamily 1, group H, member 4 Mus musculus 14-17 30580099-11 2019 Activation of FXR by agonist obeticholic acid repressed the expression of ACSL1 protein and mRNA in the liver of FXR wild-type mice but not in FXR knockout mice. obeticholic acid 29-45 acyl-CoA synthetase long-chain family member 1 Mus musculus 74-79 30580099-11 2019 Activation of FXR by agonist obeticholic acid repressed the expression of ACSL1 protein and mRNA in the liver of FXR wild-type mice but not in FXR knockout mice. obeticholic acid 29-45 nuclear receptor subfamily 1, group H, member 4 Mus musculus 113-116 30580099-11 2019 Activation of FXR by agonist obeticholic acid repressed the expression of ACSL1 protein and mRNA in the liver of FXR wild-type mice but not in FXR knockout mice. obeticholic acid 29-45 nuclear receptor subfamily 1, group H, member 4 Mus musculus 113-116 30674010-0 2019 Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model. obeticholic acid 66-82 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 37-57 30674010-2 2019 We have recently demonstrated a protective effect of the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) in rat models of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) and bleomycin-induced pulmonary fibrosis. obeticholic acid 92-108 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 57-77 30674010-2 2019 We have recently demonstrated a protective effect of the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) in rat models of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) and bleomycin-induced pulmonary fibrosis. obeticholic acid 92-108 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 79-82 30674010-2 2019 We have recently demonstrated a protective effect of the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) in rat models of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) and bleomycin-induced pulmonary fibrosis. obeticholic acid 110-113 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 57-77 30674010-2 2019 We have recently demonstrated a protective effect of the farnesoid X receptor (FXR) agonist obeticholic acid (OCA) in rat models of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) and bleomycin-induced pulmonary fibrosis. obeticholic acid 110-113 nuclear receptor subfamily 1, group H, member 4 Rattus norvegicus 79-82 31308634-0 2019 The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. obeticholic acid 55-71 nuclear receptor subfamily 1, group H, member 4 Mus musculus 43-46 31227742-1 2019 Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor alpha/delta (PPAR-alpha/delta), respectively. obeticholic acid 0-16 nuclear receptor subfamily 1, group H, member 4 Mus musculus 87-107 31227742-1 2019 Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor alpha/delta (PPAR-alpha/delta), respectively. obeticholic acid 0-16 nuclear receptor subfamily 1, group H, member 4 Mus musculus 109-112 31227742-1 2019 Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor alpha/delta (PPAR-alpha/delta), respectively. obeticholic acid 0-16 peroxisome proliferator activated receptor alpha Mus musculus 123-177 31227742-1 2019 Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor alpha/delta (PPAR-alpha/delta), respectively. obeticholic acid 0-16 peroxisome proliferator activated receptor alpha Mus musculus 179-189 31227742-1 2019 Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor alpha/delta (PPAR-alpha/delta), respectively. obeticholic acid 18-21 nuclear receptor subfamily 1, group H, member 4 Mus musculus 87-107 31227742-1 2019 Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor alpha/delta (PPAR-alpha/delta), respectively. obeticholic acid 18-21 nuclear receptor subfamily 1, group H, member 4 Mus musculus 109-112 31227742-1 2019 Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor alpha/delta (PPAR-alpha/delta), respectively. obeticholic acid 18-21 peroxisome proliferator activated receptor alpha Mus musculus 123-177 31227742-1 2019 Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor alpha/delta (PPAR-alpha/delta), respectively. obeticholic acid 18-21 peroxisome proliferator activated receptor alpha Mus musculus 179-189 30896855-0 2019 Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR. obeticholic acid 21-37 nuclear receptor subfamily 1 group H member 4 Homo sapiens 14-17 30896855-0 2019 Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR. obeticholic acid 21-37 scavenger receptor class B member 1 Homo sapiens 73-78 30896855-2 2019 Our previous study demonstrated that the activation of FXR by obeticholic acid (OCA) lowered plasma HDL-cholesterol levels and increased the hepatic mRNA and protein expression levels of SR-BI in hypercholesterolemic hamsters, but not in normolipidemic hamsters, suggesting that dietary cholesterol may be involved in the OCA-induced transcription of SR-BI. obeticholic acid 62-78 nuclear receptor subfamily 1 group H member 4 Homo sapiens 55-58 30896855-2 2019 Our previous study demonstrated that the activation of FXR by obeticholic acid (OCA) lowered plasma HDL-cholesterol levels and increased the hepatic mRNA and protein expression levels of SR-BI in hypercholesterolemic hamsters, but not in normolipidemic hamsters, suggesting that dietary cholesterol may be involved in the OCA-induced transcription of SR-BI. obeticholic acid 62-78 scavenger receptor class B member 1 Homo sapiens 187-192 30896855-2 2019 Our previous study demonstrated that the activation of FXR by obeticholic acid (OCA) lowered plasma HDL-cholesterol levels and increased the hepatic mRNA and protein expression levels of SR-BI in hypercholesterolemic hamsters, but not in normolipidemic hamsters, suggesting that dietary cholesterol may be involved in the OCA-induced transcription of SR-BI. obeticholic acid 62-78 scavenger receptor class B member 1 Homo sapiens 351-356 30896855-2 2019 Our previous study demonstrated that the activation of FXR by obeticholic acid (OCA) lowered plasma HDL-cholesterol levels and increased the hepatic mRNA and protein expression levels of SR-BI in hypercholesterolemic hamsters, but not in normolipidemic hamsters, suggesting that dietary cholesterol may be involved in the OCA-induced transcription of SR-BI. obeticholic acid 80-83 nuclear receptor subfamily 1 group H member 4 Homo sapiens 55-58 30896855-2 2019 Our previous study demonstrated that the activation of FXR by obeticholic acid (OCA) lowered plasma HDL-cholesterol levels and increased the hepatic mRNA and protein expression levels of SR-BI in hypercholesterolemic hamsters, but not in normolipidemic hamsters, suggesting that dietary cholesterol may be involved in the OCA-induced transcription of SR-BI. obeticholic acid 80-83 scavenger receptor class B member 1 Homo sapiens 187-192 30896855-2 2019 Our previous study demonstrated that the activation of FXR by obeticholic acid (OCA) lowered plasma HDL-cholesterol levels and increased the hepatic mRNA and protein expression levels of SR-BI in hypercholesterolemic hamsters, but not in normolipidemic hamsters, suggesting that dietary cholesterol may be involved in the OCA-induced transcription of SR-BI. obeticholic acid 80-83 scavenger receptor class B member 1 Homo sapiens 351-356